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One	
  of	
  the	
  key	
  properties	
  of	
  proteins	
  is	
  that	
  they	
  exhibit	
  remarkable	
  affinities	
  

and	
  specificities	
  for	
  small-‐molecule	
  and	
  peptide	
  binding	
  partners.	
  	
  To	
  improve	
  the	
  
success	
  rate	
  of	
  rational,	
  computational	
  protein	
  design	
  and	
  widen	
  the	
  scope	
  of	
  
potential	
  applications,	
  it	
  is	
  useful	
  to	
  define	
  generalized	
  strategies	
  and	
  automated	
  
methodology	
  to	
  improve	
  and/or	
  alter	
  the	
  affinity	
  and	
  specificity	
  of	
  interactions.	
  I	
  
have	
  implemented	
  several	
  strategies	
  for	
  engineering	
  protein-‐small	
  molecule	
  
interactions	
  including:	
  improvement	
  of	
  substrate	
  accessibility,	
  stabilization	
  of	
  the	
  
bound	
  state,	
  truncation	
  and	
  surface	
  engineering,	
  and	
  transplantation	
  of	
  residue	
  
level,	
  native	
  (or	
  native-‐like)	
  interactions.	
  Each	
  strategy	
  was	
  applied	
  to	
  one	
  or	
  more	
  
model	
  protein,	
  and	
  the	
  resulting	
  changes	
  in	
  affinity,	
  specificity,	
  and	
  activity	
  were	
  
characterized	
  experimentally.	
  Finally,	
  we	
  designed	
  a	
  biomolecular	
  tool-‐kit,	
  
consisting	
  of	
  17	
  engineered	
  proteins	
  for	
  amino	
  acid	
  side-‐chain	
  recognition	
  and	
  a	
  
single	
  enzyme	
  to	
  catalyze	
  the	
  Edman	
  degradation.	
  We	
  profiled	
  the	
  affinity	
  and	
  

xii	
  

specificity	
  of	
  each	
  protein,	
  and	
  implemented	
  a	
  computational	
  framework	
  that	
  
demonstrates	
  its	
  utility	
  for	
  amino	
  acid	
  calling	
  in	
  a	
  single	
  molecule	
  protein	
  
sequencing	
  assay.	
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CHAPTER 1:
INTRODUCTION
DNA sequencing has rapidly advanced the study of genomics while
advancements in proteomics have lagged behind (Figure 1). This is primarily due to a
lack of technological tools that allow us to sequence proteins with a high-throughput
assay. A major hurdle to protein sequencing is the absence of natural enzymes and
biomolecules that enable the probing of peptides in an amino acid specific way. For
nucleic acids, the canonical base pairs coupled with an abundance of enzymes that
incorporate these base pairs reduces the problem to a question of measurement. That is,
how do we measure incorporation of different bases into DNA? A vast number of
extraordinarily innovative approaches have been developed and we are now able to
sequence DNA in an incredibly fast and cost effective way. For protein sequencing there
is no replication process analogous to PCR for DNA, so the approach to sequencing must
be a single-molecule one. Our collaborators in Rob Mitra’s lab have developed an
approach that, at a single molecule resolution, images successive amino acids in a peptide
by degrading the peptide chain from the N-terminus. The missing piece of a functional
sequencing technology is amino acid identification. The question then becomes: how can
we identify individual amino acids in a side-chain specific way?

Our contribution consists of the engineering and analysis of a protein-based toolkit for single molecule sequencing. In developing this tool-kit, a number of strategies for
improving and/or altering proteins to achieve the realization of target activities and
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specificities were explored. These strategies constitute an important component of the
rapidly developing computational protein design field in and of themselves, while the
tool-kit represents an enabling component of a revolutionary way to achieve a highthroughput scale in proteomics.

In Chapter 2, I will describe our initial selection of scaffolds and a minimalist
approach to engineering a set of N-terminal amino acid binding proteins (NAABs) and
describe their characterization. These NAABs form the basis for a tool-kit which is a
critical component of a novel protein sequencing technology (Figure 2), digital analysis
of proteins by end sequencing (DAPES). In Chapter 3 I will describe a computational
framework for identification of amino acids using the tool-kit that we have developed and
show how it can be coupled with DAPES to achieve high-throughput identification of
protein sequences with high confidence. In Chapter 4, I will describe a general strategy
for improving the stability of engineered proteins. Protein stability is a major limitation in
the use of engineered proteins for applications that require robust, insensitive
components. Chapter 5 will focus on a computational technique, motif-based design,
which we have extended to design protein-small molecule interactions. This approach is
generalizable to a wide range of enzyme redesign problems. Chapter 6 will focus on our
efforts at the computational design and biophysical characterization of a novel enzyme to
catalyze the Edman degradation. This component of the DAPES tool-kit will alleviate the
need for harsh chemical treatments during the assay. Chapter 7 will summarize the
important conclusions from my work and discuss a few potential future directions.
	
  

Protein Design
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Over the past decade, advances in computational and experimental analysis of
protein structure have led to the design of proteins with novel structures and activities.
From thermo-stabilization to enhance structural stability	
  (1-11) to the transplantation of
tailored active sites into protein scaffolds to create new enzymes	
  (12-17), a number of
groups have provided evidence that rational protein design is feasible and rapidly
becoming a useful field of research. Protein engineering has shown extraordinary
potential for generating new designs for therapeutic drugs and biomolecules to treat
and/or prevent cancers (18-22), genetic diseases (23-25), and other types of metabolic
diseases (26-29). There is also excitement at the possibility that engineered industrial and
pharmaceutical enzymes will enable us to produce valuable and desirable chemicals at
lower costs while simultaneously being more efficient and a reduced these industries
impact on the environment (30-35).

Protein design can be roughly broken into two categories: rational design (36, 37)
and directed evolution	
  (38-42). The latter relies on the strategic choice of selection
schemes to harness cellular processes to generate proteins that satisfy a specific
functional requirement. Directed evolution has become the predominant method of
protein engineering primarily because, given a suitable experimental design, success is all
but guaranteed. The ability to target mutations to specific locations on a protein or
mechanisms of action or to insert completely novel activities is, however, reduced in
directed evolution. Additionally, the ability to identify and/or control the mode by which
a mutation alters activity is often diminished (43, 44).
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By contrast, rational, knowledge-based protein design relies on the engineer’s
knowledge of protein structure and macromolecular interactions to choose mutations
based on suspected or projected consequences. The advantage being that if generalizable
principles can be identified, the development of novel, designer macromolecules for
biotechnology and therapeutics would become more rapid and cost effective. The
drawback is that success-rate of rational engineering endeavors is relatively low (45), a
direct reflection of the state of knowledge regarding determinants of macromolecular
specificity, affinity and protein structure and function.

Protein Structure
Proteins are biologically synthesized linear polypeptide chains composed of
combinations of amino acids that fold into a specific conformation or ensemble of
conformations. The primary structure of a protein is defined by its linear sequence of
amino acids, which uniquely determines the protein’s identity. The 20 canonical, alphaamino acids that make up the polypeptide chain are shown in Figure 3. Amino acid side
chains exhibit a wide range of sizes, from 10 heavy atoms for tryptophan to none for
glycine, and a similarly wide range of chemical properties. It is the diverse physiochemical structure of these amino acids that govern the formation of higher order protein
structures, and the activities that they impart.

Secondary structure refers to the localized formation of alpha-helices, beta-sheets
and other turn/helix structures (Figure 4), while tertiary structure refers to the 3dimensional structure of a protein monomer (see examples in Figure 5), often referred to
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as ‘folds.’ Folds are largely driven to form by non-specific, hydrophobic interactions but
are stabilized by specific tertiary interactions like salt bridges and disulfide bonds. It is
the folded structure of proteins that imparts such characteristics as enzymatic activity and
molecular recognition.

Molecular Recognition
Molecular recognition plays a critical role in many biological functions including
antigen-antibody recognition (protein-protein), gene expression (protein-DNA), and
cellular signaling (protein-ligand). Recognition of small-molecule and peptide substrates
is primarily achieved by complementarity at the level of tertiary structure. To achieve the
exquisite affinities and specificities seen with biological molecules, these complementary
regions rely heavily on steric fit, electrostatic complementation, and hydrogen bond
patterning (46-48).

An example is the biotin-streptavidin interaction (Figure 5), in which a small
molecule (biotin) binds to a surface cleft in a small protein (streptavidin) with the
remarkably strong affinity of 10-14 M (49-51). The binding pocket for biotin shows very
high shape complementarity, and there are 8 direct hydrogen bonds (involving 7 distinct
residues on streptavidin) made to the substrate. The biotin-binding pocket is highly
hydrophobic and there are extensive van der Waals contacts made between biotin and
streptavidin, which are thought to account for much of the high affinity (52). Finally,
binding of biotin is accompanied by the stabilization of a flexible loop that closes, with a
mechanism that resembles the lid of a container, over the binding pocket and enhances
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the extremely slow dissociation rate	
  (52). Protein engineering seeks to understand and
harness interactions such as these to meet the various demands for specific applications.

Structure-based, Computational Protein Design
Rational protein design utilizes the detailed knowledge of protein structure,
function and physical characteristics to select amino acid mutations that will result in
targeted functional changes (53, 54). While this has the advantage of being inexpensive,
relatively fast and technically simple, there are several major pitfalls. Detailed structural
knowledge (i.e. a X-ray crystal or NMR structure) of a protein scaffold is required to
begin the design process, and it can be very difficult to accurately predict the effect of
various mutations, especially in the case of combinatorial or supporting mutations.

Computational protein design programs seek to aid in the identification of
favorable amino acid substitutions that improve the energetics of protein-protein, proteinligand and protein-DNA interactions. Several computational frameworks are being
productively used to engineer novel molecules (55-60). While the algorithms differ in
some of the details, there are several common components to computational design
techniques. In particular:
1. Force-field – Specifically enumerates energetic contributions to the stability
of a structure or complex. Force-fields can be either general (globally applied
to an entire structure) or local (specific to an interface or region). The former
are usually physics based (61-66), that is, they rely on a formulation of van
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der Waals energies, a solvation model and electrostatic interactions, while the
latter are often knowledge based, statistical potentials generated by sampling
from the PDB (67-72).
2. Amino acid alphabet – An alphabet of amino acids that can be used to target
the desired functional state. This can range from a subset of canonical amino
acids that are appropriate for a specific region (e.g. hydrophobic residues in
the core of a protein) to an enhanced alphabet which includes modified and
unnatural amino acids (e.g. phospho-amino acids or acetyl-alanine) (73-75).
3. Rotamer libraries – A library of conformations for each member of the amino
acid alphabet that allows exploration of the conformational space for
candidate mutations. Rotational isomers, or rotamers (76-79) from these
libraries are made up of physically accessible conformations, and are often
‘weighted’ according to their observed occurrence in the protein data bank
(80, 81).
4. Search algorithm – A computational technique for identifying the optimal
rotamer conformation and amino acid identity at a target position. This and
the force-field are the main components that differ between available software
suites. For example, RosettaDesign (59, 60) uses a Monte Carlo search to
identify low energy conformations, while alternative programs use
deterministic algorithms such as dead-end elimination.
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Ultimately, the goal of any computational design algorithm is to identify novel
amino acid sequences that are low in energy when folded into a target structure or a
multimeric complex. The two primary challenges of computational design are: the sheer
size of the amino acid-rotamer conformational space and the selection of a suitably
detailed energy function that is accurate enough to distinguish between many low-energy
structures, yet simple enough to remain computationally efficient. This latter requirement
has largely limited the terms used in design energy functions to pair-wise factorable
formulations of molecular interactions.

Using the described computational methods, a number of significant milestones in
protein design have been achieved. A common application of computational design, for
example in protein-protein or protein-substrate pairs, is to increase the affinity of
interactions	
  (82-85). Engineered protein variants that bind with a stronger affinity than
native interactions are helpful for studying existing examples of protein interactions, and
they may additionally have other applications such as protein therapeutics or other
biotechnological applications	
  (86, 87). A powerful example of a proof-of-concept design
success in this context is the improvement of the affinity of antibody-antigen interactions
beyond in vivo levels	
  (88, 89).

The specificities of protein-DNA interactions have been altered to generate DNA
cleaving enzymes with novel cut sites (90-92), as well as synthetic transcription factors	
  
(93, 94). Engineering of protein-substrate interactions often take the form of enzyme
design. Recently, there have been several successes in the design of enzymes with novel
8	
  

activities	
  (16, 17). The design of novel structures is also a goal of protein design. An
entirely novel fold has been designed, de novo, from it’s primary sequence. The resulting
protein, dubbed Top7, folded stably into a tertiary conformation not yet observed in
known proteins	
  (95). Computational design has also recently been used to engineer
complex molecular structures assembled from multiple protein domains (96).

Despite the impressive array of results demonstrated by the protein design
community, the majority of notable projects have thus far been limited in scope, and been
more focused on proving the feasibility of specific approaches than on novel,
biotechnological or industrial applications. For example, while there is widespread
sentiment that protein-based therapeutics represents a vast and relatively underexplored
potential for pharmaceutical use (97-100), that field of study is heavily focused on
discovery rather than on design. In all likelihood, this is because no significantly
designed (or redesigned) protein-based drug has, to date, been definitively shown to be
more effective than naturally produced products (98). The temporal investment and
restrictions associated with the necessity of choosing an efficient selection scheme are
often seen as a deterrent from pursing therapeutic protein engineering, at least for
exploratory designs. Additionally, the relatively low success rate of computational design
in creating novel, bio-active molecules has thus far proved unattractive enough to prevent
regular use.

In order to increase the practicality and improve the success rates of
computational approaches to protein engineering, the enumeration of specific,
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generalized design principles is critical. These generalized design principles, some of
which I will demonstrate in my thesis work, are applicable to a variety of design
problems and have the potential to improve computational protein design results.

Methods in computational protein design
The force-fields used in computational protein design can be classified in two
primary categories: knowledge-based and physics-based. Knowledge-based energy terms
rely on statistical information about amino acid preferences, conformations, and
interactions derived from the PDB (67-72). A typical example of a knowledge-based
energy term is the quantification of the well-described phenomenon that hydrophobic
residues prefer to remain in contact with each other, and prefer to minimize their solvent
accessibility. This statement is quantified into an energy by extracting statistics regarding
the placement of a hydrophobic residue in all known protein structures. The Boltzmann
function (based on, for example, the distribution of distances between a hydrophobic
residue and all of its hydrophilic neighbors) can then be used to generate a derived energy
function (71, 72, 101). This type of force-field essentially allows the engineer to vary
amino acids (i.e. simulate mutations) while maintaining near native contacts and
conformations, but strongly favors interactions which have been previously observed.
While this has generally shown to be helpful in realized designed interaction, there is
potential to miss favorable conformations.

Physics based force-fields attempt to reconstruct the interactions of amino acids in
a protein from first principles (61-66). Arguably, the most well-known physics-based
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energy term is the Lennard-Jones potential, which is an approximation describing the
steric attractive and repulsive interactions between atoms. Energy terms such as the
Generalized Born formulation of electrostatic interactions (102), and the LK solvation
model (103) are further examples of physics based functions.

This work will focus on the use and extension of the RosettaDesign algorithms.
RosettaDesign is a computational framework originally introduced in (59, 60), which has
been extensively and successfully used by the protein engineering community.
RosettaDesign uses a hybrid energy function to model mutations in a fixed backbone
structure. Various combinations of knowledge-based and physics-based terms are
utilized, depending on the application and system being modeled.

Applications in computational protein design
The monumental proof-of-principle successes mentioned above, along with
increasingly standardized and codified approaches to computational protein engineering
have led to the emergence of applied protein design. This thesis is largely devoted to
strategies for applied protein design along with an important application to technology
development, hence I have outlined a few of the most significant advances in applied
design fields below.

Therapeutics
Protein therapeutics have been repeatedly shown to demonstrate very high levels
of potency and safety. They have also been able to address a number of previously unmet
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needs in the pharmaceutical industry. PROLOR Biotech Inc. was the first company to
supply a definition of therapeutic proteins as “those that are either extracted from human
cells or engineered in the lab for pharmaceutical use” (PROLOR Biotech Inc., 2006).
This categorization includes natural, recombinant proteins that are expressed in
microorganisms and used as replacement therapies (e.g. insulin) as well as novel,
designed proteins. We typically think of small molecules when we define what a drug is;
however, therapeutic proteins have a number of definable advantages over small
molecules. These advantages include a higher specificity than small molecules, which
helps to reduce the possible side effects, less likelihood to be attacked by the immune
system since many proteins are already present on the body, and efficient enzyme
replacement treatments for certain genetic disorders which does not require more
technically difficult gene therapies (104).	
  

Biosensors
Protein engineered biosensors provide the next best step in the advancement of
protein-based sensors that can specifically identify chemical substrates. For example, a
group engineered a FRET-based calcium biosensor employing troponin C as calciumbinding moiety (105, 106). The resulting biosensor exhibited fast kinetics, was stable in
imaging experiments, and showed a significantly enhanced change in fluorescence.
Biosensor design is a very active field of research with several centers focused on the
task emerging in recent years.

Biocatalysts
12	
  

Over the past ten years, scientific and technological advances have established
biocatalysis as an economical and environmentally friendly alternative to more
traditionally used processes such as metallo- and organocatalysis in chemical production
both in the laboratory and on an industrial scale. Engineering enzymes to improve the
methods by which we produce biofuels has also been an active area of interest (107-109).
In this area, rational design offers opportunities to enhance biocatalysts instead of
accepting sub-optimal kinetic or interaction properties as limitations in natural cellular
biofuel ‘factories’. For example, the molecular stability of the enzymes themselves
frequently determine the useful lifetime of biofuel cells (110-112). Successful
engineering strategies for increasing protein stability, including core redesign and surface
‘supercharging’, can be readily applied to the protein components of a biofuel cell to
improve its efficiency or expand its applicability. For example, a group recently
stabilized human carbonic anhydrase II (HCA II), which functions near diffusion-limited
efficiency at room temperature. As temperature increases, however, its activity is rapidly
attenuated (113). Improved thermal stability allows this enzyme to be used in very hightemperature applications such as carbon sequestration from CO2 produced by coal power
plants (114).

Additionally, biocatalytic enzymes have been extensively improved for a variety
of pharmaceutical applications and form a vital component in the production of a number
of active pharmaceutical ingredients (APIs). There are many examples, including an
engineered transaminase for the synthesis of Januvia® (improved up to 28,000-fold using
well-established protein design techniques), and haloalkane dehalogenases with over
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4000-times the activity of native enzymes for synthesizing two widely used drugs,
Lipitor® and Singulair® (Codexis).

Nanotechnology
Engineered protein-polymer composites present a large number of physical
properties and chemical compositions that can potentially be utilized as components in
prosthetics, medical devices, and tissue-engineered applications	
  (115-118). Biomaterials
combine the advantages of many common industrial materials, such as reproducibility
and easy customization, with the advantages of natural materials, such as cell
compatibility and biodegradability	
  (119). As one example, Heilshorn et al. have designed
protein materials that blend the elastic-like mechanical properties of synthetics with celladhesive biochemical properties (120, 121). Recently, de Grado et al. designed a selfassembling nano-fibre, which consisted of a helical bundle that cooperatively selfassembled onto the surface of a carbon nanotube demonstrating that synthetic-biological
materials can be effectively designed (122).

My thesis work will apply the novel approaches to protein design that I’ve
developed to create a biomolecular tool-kit for protein sequencing. To the best of my
knowledge, this tool-kit represents the largest system of designed proteins for a
biotechnological application thus far attempted.

Protein Sequencing
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Automated protein sequencing has evolved considerably with greater sensitivity,
speed and ease of operation. The vast majority of protein sequencing is currently done
using two primary experimental methods—mass spectrometry (MS) and a process called
Edman degradation. Mass spectrometry is the most heavily developed methods and is
becoming wide spread due to technological advances and improved computational
techniques for analyzing outputs (123, 124). MS has a number of significant weaknesses
which limit it’s ability to fully resolve the proteome in a high-throughput way	
  (125).

Mass spectrometry
While mass spectrometry techniques for sequencing a proteome have advanced
considerably, the quantitation of a complete set of proteins from a biological system
remains an unresolved problem (125). Application of current mass spectrometry
techniques have led to a coverage of over 50% in single celled organisms. However,
coverage beyond around 10% has proven elusive in more complex organisms. If we
consider only proteins that can be quantified, the numbers are significantly lower
primarily because the range of physiochemical characteristics of amino acids renders it
difficult to quantify mass spectrometry data(126-128).

For example, de novo sequencing is based on mass. Several amino acids have the
same masses (e.g. leucine and isoleucine), which makes distinguishing between these two
relatively common amino acids difficult (129, 130). This makes the very frequently
occurring hydrophobic peptides from protein cores difficult to map. Peptides fragmented
15	
  

by mass spectrometry can also lose neutral chemical groups (e.g. NH3) which obscures
the source of the peptide by affecting the mass measurement (131, 132). Protein
identification using mass spectrometry is also heavily dependent on existing databases of
genomic sequences (133, 134). Additionally, splice variants and alternative isoforms are
particularly difficult to recognize using mass spectrometry. Because approximately 74%
of human genes are alternatively spliced, this presents a problem that makes it difficult to
account for the full molecular diversity of proteins (135-137). While mass spectrometrybased proteomics remains an invaluable tool and is (arguably) the most actively
developed high-throughput approach to proteomics, these points illustrate several
potential pitfalls at different levels of the process. A reasonable assessment of the field of
proteomics would be that we remain relatively far from being able to generate
quantitative proteomic sequence data at a large enough scale to allow comprehensive
interrogation of most biological phenomenon.

Edman Degradation
The other method commonly used for protein sequencing is the Edman
degradation reaction. This involves either a whole or digested protein with an exposed Nterminus. The N-terminus is then chemically modified allowing removal amino acids one
at a time, then identifying each using chromatography (Figure 2) (138, 139). Efficiencies
of all steps within the Edman sequencing process are generally around 98%, which
allows proteins or peptides of up to 50 amino acids in length to be determined with a high
level of accuracy (140). Sequencing by Edman degradation is a well-developed
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technique, with automated sequencers being currently utilized in proteomic centers (141).
The primary drawback to Edman degradation is that it is inherently low throughput,
requiring a sample of a single, highly purified protein. Because of this, Edman
degradation has been largely abandoned in the current drive for high-throughput,
systems-wide biology.

Recent developments in proteomics
While protein sequencing by mass spectrometry and Edman degradation are both
developed fields, there are a number of newer technologies that are being actively
developed for systems level proteomics research. Perhaps the most well-developed and
promising technology is being developed by Somalogic, which utilizes a series of slow
off-rate modified aptamers (SOMAmers) to target each protein in the human proteome.
Currently, SOMAlogic can accurately quantify 1,129 proteins across around eight logs of
concentration, with a goal of 6,000 proteins by the end of 2014 (142-144). The inherent
limitation of this technique is that it does not determine the primary sequence of the
targeted proteins, thus limiting it’s applicability to the discovery of novel biomarkers for
disease states, and the ability to distinguish alternative isoforms including posttranslational modifications.

DNA sequencing using nanopores is considered a third generation DNA
sequencing technology that is just coming into commercial use (145). Nanopore
sequencing relies on differential current drops as different bases pass through a small
biological pore (146). Recently, there have been several papers that have laid the

17	
  

groundwork for sequencing peptide chains using the same technology (147-150). In
contrast to SOMAlogic’s approach, this would yield protein primary sequence
information on par with mass spectrometry. This technology is in a very early stage with
a number of proof-of-principle experiments that still need to be completed. To the best of
my knowledge, however, this is the only novel protein sequencing technology currently
being developed which would provide the same level of information as the assay
described in this thesis.
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FIGURE 1: Number of papers in proteomics and genomics from 2000-2013. A
keyword search on PubMed illustrates that papers using genomics techniques,
specifically DNA sequencing and analysis, are far more prevalent than proteomics
research.
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FIGURE 2: DAPES and the Edman reaction. A schematic of the proposed protein
sequencing method, DAPES, is shown in (A). N-terminal amino acids are bound with a
flouresent probe and imaged. The bind-image cycle is repeated for a probe specific to
each amino acid. All N-terminal amino acids on the array are then removed using the
Edman degredation (B), and the process is repeated to identify the primary sequence of
each peptide on the array.
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FIGURE 3: The 20 canonical amino acids. Molecular structures and selected properties
are shown below. These serve both as the building blocks for protein design and illustrate
the difficulty of engineering a set of probes which binds each side chain with specificity.
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FIGURE 4: Protein secondary structure types. Shown in blue are examples of alphahelices (A), beta-sheet regions (B), short beta-turn (C), extended beta turn (C, red), and
disordered loop region (D).
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FIGURE 5: Examples of protein folds. (A) The number of classified protein folds from
the SCOP database from 1997 to 2013. No new folds have been identified since 2008.
(B) One of the first structures determined was that of myoglobin, which exhibits an
alpha-helical fold and binds a heme cofactor (PDB 1TES(151)). (C) A beta-barrel protein
from pseudomonas (PDB 4FOZ(152)). (D) The Rossman fold, a member of the alphabeta superfamily (PDB 3PTJ(153)). (E) The first novel fold achieved by computational
design, Top7 (PDB 1QYS(95)).
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FIGURE 6: Biotin-streptavidin interaction, one of the strongest non-covalent
interactions known. The high specificity and affinity are achieved using many of the
physical interactions that protein design seeks to harness including steric
complementarity, extensive hydrogen bonding networks, and surface electrostatics. The
various force-fields used in computational design allow us to create and modify these
interactions to achieve novel affinities and activities.
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FIGURE 7: Computational protein design methods. (A) Several examples of
fundamental physics-based energy functions used in computational protein design. (B)
An example of a knowledge based energy, the amino acid dependence of backbone
torsion angles.
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CHAPTER 2:
MINIMAL ENGINEERING OF A SET OF NTERMINAL AMINO ACID BINDING
PROTEINS FROM tRNA SYNTHETASES
This chapter consists of work that will be combined with chapter 3 in a manuscript that is
currently being prepared for publication. I carried out all of the experiments, which were
conceived by Jim Havranek and myself.
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ABSTRACT
The studious choice of scaffolds is a critical component of successfully designing
functional proteins. As our database of protein structures rapidly grows, the chance of
finding a design scaffold with a function or specificity similar to the design target also
increases. It is therefore desirable to test and catalogue general strategies for altering or
improving native interactions in a way that is minimally disruptive to the rest of the
protein. These approaches are also useful when naturally occurring proteins provide
inherent specificity that would otherwise be extremely difficult to design. In this chapter,
I enumerate several of these strategies and implement them to improve the affinity of
amino-acid tRNA synthetases, the basis of our molecular tool-kit of NAABs. I also
characterize a series of native and truncated synthetases that are utilized in the formation
of a biomolecular tool-kit for single molecule protein sequencing.
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INTRODUCTION
Rational protein design can refer either to the de novo, “bottom-up” design of a
folded, functional molecule, designed directly from primary sequence or to the redesign
of existing protein scaffolds (1). The former provides a stringent and comprehensive test
of our knowledge of protein structure, folding, stability and function and represents the
ultimate goal of protein engineers. The combinatorial complexity of predicting a folded
protein conformation from primary sequence renders such engineering efforts
extraordinary difficult. Despite this difficulty, several groups have made strides in this
type of protein design (2-9). Nearly all practical design problems, however, have relied
on protein redesign, or “top-down” design	
  (10-15). In this approach, a known, stable
scaffold is repurposed to produce a new protein with altered enzymatic or interaction
activity. Top-down design makes use of the hypothesis that nature has already supplied
the ambitious protein engineer with a wide variety of building blocks to generate a vast
number of proteins with practical applications in biotechnology.

While the top-down design concept is the cornerstone of protein engineering by
directed-evolution techniques, it has also been heavily utilized by the rational design
community. Several groups have implemented variations on this strategy both as proofof-principle and in practical applications. Novel protein-protein interfaces have been
designed which have native-like or better affinities (11). The DNA specificity of both
transcription factors and restriction enzymes has been successfully altered (10, 16-18).
Enzymes have been re-designed to catalyze new reactions or alter the balance of
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intermediate products in metabolic pathways (19-22). One group has rationally redesigned a cellular entry protein to change the organism specificity of an invasive
microbe (23). Here we extend the minimalist design principles associated top-down
redesign to generate a novel tool-kit for a biotechnological application: single-molecule
protein sequencing.

Recently, a technique has been proposed for sequencing individual peptide chains
using single-molecule imaging via Total-internal Reflectance microscopy (TIRFm). The
assay, dubbed Digital Analysis of Proteins by End Sequencing (DAPES), revolves
around sequential sequencing of short peptide reads using parallelized Edman
degradation. Briefly, a complex mixture of proteins is digested into short fragments and
immobilized onto a slide. Fluorescently labeled probes specific to each individual, Nterminal amino-acid side chain are then flowed over the surface, and the bound probe is
imaged using TIRFm to determine the identity of each N-terminal amino acid on the
slide. Next, the N-terminal amino acid is removed from each peptide chain by Edman
degradation, and the process is repeated sequentially. This process is summarized in
Figure 8.

To help make DAPES feasible, we have implemented minimalist protein design
on a series of strategically chosen scaffolds to generate a set of N-terminal Amino Acid
Binding probes (NAABs) that recognize each side chain with varying specificity.
Furthermore, we have experimentally characterized a complete set of NAABs using
native and designed probes for identifying each of the canonical amino acids. Our results
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demonstrate that the each NAAB exhibits an affinity for its cognate amino acid with a KD
no worse than the µM range, and that the set of NAABs contains a minimum of four
distinct groups of specificity profiles.

RESULTS
Modeling and selection of truncations
The physio-chemical similarity of many groups of amino acids makes engineering
NAABs exceptionally challenging, hence an appropriate starting point is critical. We
choose to use the amino acid tRNA syntheses (aaRSs). aaRSs are a critical component of
protein biosynthesis in all known organisms. Each aaRS is an enzyme that binds it's
cognate amino acid and it's cognate tRNA, then catalyzes the amino-acylation reaction to
charge tRNAs which then have their newly attached amino acid incorporated into a
growing peptide chain by the ribosome (24). The advantage of the aaRSs for our
application is that they have natural affinity and specificity for each amino acid sidechain. A disadvantage is that many aaRSs are known to bind their tRNA and amino acid
cooperatively (25-27), hence the absence of one binding partner (the tRNA in our case)
may decrease the affinity or specificity for it's cognate amino acid.

Several structural models for each aaRS are available in the PDB (Table 1). Using
this structural data, we observed that most aaRSs have a distinct domain for binding the
amino-acid and a distinct domain for binding the tRNA. We reasoned that removal of the
tRNA binding domains would reduce the need for tRNAs to simultaneously bind in
concert with the cognate amino acid. Using the available structures as templates, we first
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generated homology models for each aaRS from E. coli. We then rationally identified
truncation mutants that led to only minor decreases in predicted Rosetta energies (28, 29)
(Figure 9). This rational, computationally aided design strategy led us to identify soluble
truncation mutants for most of the aaRSs. A few were either already monomers or had
suitable truncations identified from previous works (Table 2).

Increasing pocket accessibility by loop redesign improves affinity of hisRS.
During the homology modeling and substrate docking, we noticed that several of
the placed peptide substrates showed significant steric clash with the surrounding NAAB
domain. While this is not surprising, considering that the aaRSs natively bind an isolated
amino acid, rather than an N-terminal amino acid, we reasoned that this could be a
potential affinity-robbing property for our NAABs. For each NAAB, we modeled the
peptide substrate with the N-terminal amino acid superimposed on the empirically
determined, bound position of the cognate amino acid. In examining the modeled
structures, we found several instances where a large loop occluded the ability of the
peptide substrate to position its N-terminus in the required location. We reasoned that
removing this obstacle could improve the binding affinity of our NAABs.

We identified a candidate loop in hisRS, which had a truncation mutant with a
high µM affinity. This loop (Figure 11) linked a pair of anti-parallel beta sheets and could
potential obstruct substrate binding, especially with the modeled peptide. In the crystal
structure, this loop has direct overlap with the third and fourth amino acid of the peptide
substrate. Furthermore, these clashes cannot be resolved by loop remodeling, energy
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minimization, or a combination of the two. One approach might be to mutate several of
the loop residues to glycine, which might allow the loop to pivot out of the pocket.
However, this could also have undesirable effects on binding depending on the dynamics,
which are difficult to model.

Instead, we chose to remove this loop at each of its termini and replace it with a
canonical, four amino acid beta-turn. This type of motif grafting has been used by
previous groups to design proteins or for structural modeling (30, 31), and is a natural
extension to fragment insertion (30, 31). The grafted loop removes all direct contact with
the modeled peptide substrate. Additionally, the Rosetta energy for the apo-design is not
significantly worse than the apo-truncation, indicating that the binding pocket should
remain unaltered.

The engineered mutant was expressed and purified as described in the methods
section, then assayed for binding affinity using BLI (see methods). The mutant exhibited
almost a full order of magnitude improvement in binding affinity, from 294.0 µM to 68.2
µM. Additionally, the improvement is almost exclusively in the association rate, while
the dissociation rate remains unchanged (Figure 11). This supports the hypothesis that
pocket occlusion was a barrier to binding the unnatural substrate.

Switching binding mechanism from induced fit to lock-and-key increases the

44	
  

affinity of metRS.
The observation that the in vitro function of the aaRSs utilizes cooperative
binding of tRNAs and amino acids motivated us to generate truncation mutants to
alleviate this codependency. We reasoned that the necessity of a cognate tRNA to
cooperatively improve binding affinity for a cognate amino acid was only partially
alleviated by the removal of the tRNA binding domain. Additional improvement to our
NAABs could potentially be gained by further decreasing the dependence of affinity on
the tRNA cofactor. A previous study generated a metRS that was demonstrated to show a
binding mechanism swap from induced fit to lock-and-key (32). This study had classified
the mutated tRNA synthetase as an active, acylating enzyme. They additionally solved
the mutant crystal structure in both apo and holo forms to determine that the binding
mechanism had been changed by their mutations. The choice of appropriate mutations
relies heavily on knowledge of both the apo and holo crystal structures, which places a
significant restriction on the generality of this approach.

We modeled a peptide substrate into the binding pocket of the mutated holo
structure. Evaluation of the Rosetta energy revealed one amino acid, an aspartate
immediately adjacent to the active site, which had poorly matched interactions with the
substrate (Figure 12). We reasoned that removing this interaction would be essential to
promoting substrate binding and thus mutated this amino acid to a glycine, which
alleviated the energetic penalty.
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The resulting mutated protein was expressed and purified as described in the
methods, and assayed for binding affinity using BLI. We found that the dissociation
constant was improved by nearly 5-fold, from 305.1 µM to 60.7 µM (Table 3). Further
characterization revealed that the affinity for several other amino acids also increased, so
the change was not specific to methionine. Both leucine and isoleucine are also bound
more tightly by the lock-and-key metRS, however, the affinity for the remaining amino
acids was unaffected.

Reengineering the surface of pheRS to improve solubility also increases its
affinity towards phenylalanine.
A third approach we used to increase the NAAB binding affinity was to stabilize
the truncation mutant. In the case of pheRS, implementing the domain truncation
drastically decreased the stability of the NAAB and led to the formation of aggregates on
the DAPES surface. Examination of the structural model showed that the truncation was
significantly different from the other aaRSs in that ~60% of the truncation’s surface area
was previously buried. A previous study demonstrated that placing large amounts of like
charge on the surface of designed proteins increased thermo-tolerance of these proteins
(33). We reasoned that we could alleviate the aggregation problem by following this
strategy.

We implemented 12 mutations on the surface of the pheRS mutant (Figure 13)
and observed a drastic decrease in surface adsorption using the single molecule detection
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surface described in (34). We then characterized the binding using BLI (described in the
methods). Surprisingly, the affinity of the pheRS for its cognate peptide substrate was
increased by approximately 16-fold (62.9 µM for the native compared to 3.91 µM for the
design). We hypothesize that this increase is due to a stabilization of phenylalanine
binding pocket, and is similar to swapping the binding mechanism as described above.

Full experimental characterization of binding affinities and cross
specificities.
The complete set of NAABs, which includes the three designed NAABs along
with 14 truncation and native tRNA synthetases, is described in Table 1. We
characterized the affinity of each NAAB for it’s cognate amino acid as well as all the
other canonical amino acids relevant to the DAPES assay (Table 3). Cysteine is omitted
since, as in DAPES, we use thiol-chemistry to couple the peptides to our surface and
have gone through considerable optimization to assure the absence of exposed thiols. We
expressed each of the truncation mutants or the engineered mutants as described in the
methods section of this chapter and characterized their binding to each N-terminal amino
acid with BLI using short, pentapeptide substrates. Many of the probes behave as
expected. Both the argRS and trpRS truncations bind their cognate amino acids with nM
affinity, and nearly all the NAABs bind their cognate substrates with at least low µM
affinity (Figure 10). This demonstrates that our computationally guided truncation
strategy produced a set of stable proteins that maintain a substantial portion of their
native recognition properties. There is, however, abundant cross specificity that we see as
strong affinities off the diagonal of the matrix.
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NAAB cross-specificities cluster according to physio-chemical
characteristics.
Having quantified all the possible binding events we wanted to determine whether
or not some NAABs were redundant. To accomplish this, we first examined how the
binding characteristics clustered between NAABs. Each NAAB possesses a vector of
binding affinities that describes its specificity profile. A hierarchical clustering algorithm
was applied to the set of vectors using the cluster package in R. Several distinct groups
emerge (Figure 14) which cluster according to their physio-chemical characteristics, for
example, the largest cluster contains the NAABs corresponding to tRNA synthetases for
hydrophobic amino acids. Similarly, the second cluster contains aaRSs for the aromatic
amino acids, the third contains aaRSs for the small polar amino acids (cysRS, serRS and
thrRS), and the fourth contains most of the larger polar aaRSs. We next performed a
factor analysis to determine if individual NAABs contained redundant information.
Figure 15 shows a scree plot of the original binding matrix and the correlation matrix.
There is little apparent structure in the original matrix, but the correlation matrix shows a
significant bend in the scree plot at four clusters. The clustered correlation matrix is
shown in Figure 16, where the four similar groups, again according to amino acid
characteristics, emerge.

DISCUSSION
We have demonstrated the utility and desirability of strategically selecting protein
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scaffolds for minimalist computational design, as well as demonstrating the ability of the
RosettaDesign framework to choose stable, active truncation mutants using current
computational design energy functions as a guide. Additionally, we have shown that our
set of truncation mutants exhibit a range of appreciable affinities for our target
application and demonstrated that we can improve these affinities using several
potentially generalizable, rational-design strategies. The set of engineered molecules
provide a potential tool-kit for protein end-sequencing using a single molecule detection
technique.

Not all of the applied strategies will lead to the same level of success with all
proteins. For example, improving pocket accessibility would do little to improve a highly
dynamic binding site. The fact that this approach was so successful with hisRS is likely
because of the change from a native substrate (histidine) to a substrate at the N-terminus
of a peptide. Similarly, it can be difficult to accomplish some of these design strategies
without a significant amount of structural knowledge. Swapping the binding mechanism
from an induced fit to a lock and key would, in general, require knowledge of both the
apo and holo crystal structures so that critical residues could be identified.

While the set of protein probes is complete in the sense that each amino acid has
an associated NAAB which binds with at least a µM affinity, these affinities vary widely
from low nM to high µM. Additionally, some NAABs have a large amount of cross
specificity. These two facts indicate that the tool-kit has plenty of room to be further
improved using protein engineering techniques should the end application necessitate it.
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Given the abundance of filtering using editing domains and tRNA specificity used by
tRNA synthetases	
  (35-42), it is unlikely that perfect specificity for each amino acid can
be achieved.

We have demonstrated several approaches that can be applied to this tool-kit to
improve NAABs including: binding pocket accessibility, surface reengineering, and
binding mechanism swapping. Ultimately, however, both the affinity and specificity of
the NAABs is limited by the physiochemical characteristics, particularly the size and
similarity, of the target substrates. This however, is not necessarily a limitation in terms
of using the toolkit in a functional proteomic assay.

MATERIALS AND METHODS
Homology modeling
Homology models were generated for each of the aaRSs by aligning the sequence
of the available crystal structure to the sequence of the E. coli homologue. This resulted
in sequence homology of between 30 % and 70%. Each experimentally determined
crystal structure was computationally mutated to match the E. coli sequence at any
aligned position using Rosetta (28). Initially, the repulsive portion of the energy function
was reduced to zero, in order to accommodate positions that might have significant steric
clash. The Lennard-Jones repulsive energy was then gradually ramped up while
performing gradient minimization, and holding the backbone in place with gradually
relaxed harmonic constraints. Following these steps, stretches of the E. coli sequence that
were insertions were rebuilt using either the fragment insertion (if it was in a region of
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defined secondary structure) or the loop rebuilding modules in Rosetta. The constrained
backbone minimization was then repeated. Finally, deleted regions were accommodated
by adding harmonic constraints to the N- and C-termini of the deletion and reimplementing the constrained backbone minimization to drag the two termini together.

Truncations were chosen by visual inspection of the domain boundaries. The
selected region (red in Table 2) was then manually removed and the resulting truncation
was scored using the Rosetta “score12” energy function (28). If the energy of the
resulting truncation was less stable by more than ten Rosetta energy units, amino acids
were added back to the truncated terminus until the energy deficit failed to decrease.

Cloning, expression and purification
Primers specific for each NAAB were ordered from Integrated DNA
Technologies (IDT). Each NAAB was then amplified from isolated, E. coli genomic
DNA and transferred to a pET42a expression vector at various positions, depending on
the gene sequence. These constructs were transformed into either E. coli BL21(DE3) or
“Arctic Express” competent cells for expression.

Protein was over-expressed following Studier’s auto-induction protocol (43).
Bacterial cells were harvested by centrifugation of the cell culture at 5000 rpm and 4
degrees for 10 minutes. Cells were then re-suspended in 1x PBS with 10% glycerol, pH
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7.4. Cells were then lysed by sonication on ice. The cell lysate was centrifuged at 18,000
rpm, 4 degrees for 20 minutes. The supernatant was then filtered through a 0.2 um
cellulose acetate filter. The filtered lysate was loaded onto a 1 mL GSTrap column and
washed with 5 column volumes of binding buffer (1x PBS). Bound protein was then
eluted in 50 mM Tris-HCl, 10 mM reduced glutathione. Purified fractions were prepared
for SDS-PAGE analysis by mixing 2 parts sample with 1 part 4x loading dye. Samples
were analyzed on 16% SDS-PAGE precast gels, and visualized by Coomassie staining.

Protein concentration was determined using the calculated molar extinction
coefficient and measuring the A280 on an ND-8000 spectrophotometer (Thermo Fisher
Scientific). Site-directed mutagenesis was accomplished using the QuikChange protocol
(Agilent Technologies) and verified by sequencing.

Binding assays
Real time binding assays between peptides and purified NAABs were performed
using biolayer interferometry on the Blitz and Octet systems (Fortebio, Menlo Park, CA).
These systems monitors interference of light reflected from the surface of a fiber optic
sensor to measure the thickness of molecules bound to the sensor surface. The
dissociation constant Kd can be determined from Kd = koff/kon, where kon is the rate of
protein binding to the material on the sensor surface (the association-rate) and koff is the
rate at which the analyte can be removed from the sensor with a buffer solution (the
dissociation-rate).
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Peptide substrates were ordered from Celtek Peptides, with a specific N-terminal
residue, and a C-terminal Cysteine. Peptides were immobilized by first activating the
surface with 1M 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 0.2M Nhydroxysuccinimide (NHS) then incubating with a bifunctional 3-Maleimidopropionic
acid hydrazide	
  (BMPH) cross-linker to introduce a sulfhydral reactive maleimide group.
Unreacted surface groups were quenched with 1M ethanolamine. Peptide was then
immobilized by reacting the C-terminal cysteine with the maleimide. Unreacted
maleimide was quenched with 50 mM cysteine.

Sensors coated with peptides were allowed to bind to the NAABs in 1x PBS at
several different protein concentrations. Sensors without peptide attached were used as
negative controls for each NAAB. Binding kinetics were calculated using the Blitz
software package, which fit the observed binding curves to a 1:1 binding model to
calculate the association rate constants. NAABs were allowed to dissociate by incubation
of the sensors in 1x PBS. Dissociation curves were fit to a 1:1 model to calculate the
dissociation rate constants. Binding affinities were calculated as the kinetic dissociation
rate constant divided by the kinetic association rate constant.

Clustering
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Hierarchical clustering was performed in the R software package. The algorithm
(44) uses a complete linkage method which starts by assigning each vector of NAAB
affinities to its own cluster, then joins the two clusters with the highest similarity and
continues until there only a single cluster remains. It utilizes a dissimilarity matrix based
on the square Euclidean distances between cluster means.

Clustering of the NAAB correlations was performed using k-means clustering in
R. The correlation of each NAABs affinity vector with all other NAABs created a 17 x
17 matrix. The within cluster sum of square errors was plotted against the number of
clusters for one to seventeen clusters and plotted as a function of cluster size to determine
the optimal number of groups.
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FIGURE 8: A schematic of DAPES (Digital Analysis of Proteins by End
Sequencing). In step 1, a digested protein sample consisting of one or more proteins is
immobilized onto a surface with its N-terminus projecting out into solution. In step 2, a
NAAB targeting a specific amino acid (or group of amino acids) is added to the slide and
positions where it binds are imaged or recorded. Following imaging, the NAAB is
removed and the process repeated for all NAABs in the tool-kit. After a single position
has been fully characterized, the Edman Degradation (either chemically or, in this case,
enzymatically) is carried out on the surface (step 4-5). The result is a regenerated surface
of N-termini with peptides 1 amino acid shorter than before. The entire process is
iteratively repeated for every amino acid on the peptide chain.
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FIGURE 9: Examples of truncation mutants from the tRNA synthetase families. (A)
Valyl-tRNA synthetase with the retained domain in blue and the two removed domains in
green. (B) A Histidyl-tRNA synthetase showing the removed multimerization domain in
green and the retained domain in blue.
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FIGURE 10: Affinity and specificity matrix for the set of 17 NAABs. Each row is a
NAAB and each column is an N-terminal amino acid, thus each spot corresponds to the
binding affinity of a NAAB for a particular amino acid. On this scale, black represents
the tightest binding NAABs (high nM affinity), and white is no binding observed.
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FIGURE 11: Binding accessibility mutations in Histidyl-tRNA synthetase. The
native conformation is shown in blue, with the inserted beta-turn motif shown in red. The
peptide substrate with an N-terminal histidine is shown in a stick representation.
Normalized sensograms for the two variants are shown below.
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FIGURE 12: Mutations in methionyl-tRNA synthetase. The mutated positions of the
metRS which resulted in a change from an induced fit to a lock-and-key binding
mechanism are shown in a stick representation. The modeled peptide is shown in a spacefilling representation.
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FIGURE 13: Surface redesign of phenylalanyl-tRNA synthetase. Swapping twelve
apolar or positively charged, solvent exposed residues on the surface pheRS removed the
aggregation problems observed on the DAPES surface. Additionally, the structural
stabilization of the scaffold improved the binding affinity of the NAAB for it’s cognate
amino acid.
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FIGURE 14: Hierarchal clustering of the NAABs. Non-iterative clustering of the
NAAB affinities leads to five distinct groups.
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FIGURE 15: Scree plot showing cluster sum of square errors compared to number
of clusters for the original matrix (left) and the correlation matrix (right). The
within-cluster sum of square error is plotted against the number of k-means clusters to
determine the appropriate number of clusters in the data set. The SSE will fall off rapidly
until the optimal number is reached. The original matrix does not show significant
grouping compared to randomized data, while the correlation matrix allows a clearer
extraction of features, and points to four distinct clusters.
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FIGURE 16: Clustered correlation matrix. Correlation of each NAAB with the rest of
the set was computed by comparing their binding affinity vectors. A factor analysis
indicates that the optimum number of factors is four, which are shown grouped within the
blue boxes.
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TABLE 1: Structural data for aaRSs.
tRNA	
  Synthetase	
  
Glutamine	
  
Arginine	
  
Alanine	
  
Phenylalanine	
  
Tyrosine	
  
Histidine	
  
Cysteine	
  
Threonine	
  
Serine	
  
Glutamate	
  
Asparagine	
  
Aspartate	
  
Glycine	
  
Isoleucine	
  
Leucine	
  
Valine	
  
Lysine	
  
Methionine	
  
Proline	
  
	
  

Number	
  of	
  Structures	
  
22	
  
6	
  
20	
  
15	
  
42	
  
12	
  
5	
  
15	
  
9	
  
18	
  
3	
  
13	
  
12	
  
11	
  
22	
  
5	
  
12	
  
28	
  
15	
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TABLE 2: Sequences of NAABs used in this study.
Arginine	
  
(1BS2)	
  

Asparagine	
  
	
  

Aspartate	
  

Cysteine	
  

mniqallsekvrqamiaagapadcepqvrqsakvqfgdyqangmmavakklgmaprqlaeqvlthldlngiaskv
eiagpgfinifldpaflaehvqqalasdrlgvstpEKQTIVVDYSAPNVAKEMHVGHLRSTIIGDAAVR
TLEFLGHKVIRANHVGDWGTQFGMLIAWLEKQQQENAGEMELADLEGFYRDAKKHY
DEDEEFAERARNYVVKLQSGDEYFREMWRKLVDITMTQNQITYDRLNVTLTRDDVM
GESLYNPMLPGIVADLKAKGLAVESEGATVVFLDEFKNKEGEPMGVIIQKKDGGYLYT
TTDIACAKYRYESLHADRVLYYIDSRQHQHLMQAWAIVRKAGYVPESVPLEHHMFGM
MLGKDGKPFKTRAGGTVKLADLLDETLERARRLVAEKNPDMPADELEKLANAVGIGA
VKYADLSKNRTTDYIFDWDNMLAFEGNTAPYMQYAYTRVLSVFRKAEINEEQLAAAP
VIIREDREAQLAARLLQFEETLTVVAREGTPHVMCAYLYDLAGLFSGFYEHCPILSAEN
EEVRNSRLKLAQLTAKTLKLGLDTLGIETVERM
msvvpvadvlqgrvavdsevtvrgwvrtrrdskagisflavydgscfdpvqavinnsllnynedvlrlttgcsvivtgk
vvaspgqgqqfeiqaskvevagwvedpdtypmaakrhSIEYLREVAHLRPRTNLIGAVARVRHTLA
QALHRFFNEQGFFWVSTPLITASDTEGAGEMFRVSTLDLENLPRNDQGKVDFDKDFF
GKESFLTVSGQLNGETYACALSKIYTFGPTFRAENSNTSRHLAEFWMLEPEVAFANLN
DIAGLAEAMLKYVFKAVLEERADDMKFFAERVDKDAVSRLERFIEADFAQVDYTDAV
TILENCGRKFENPVYWGVDLSSEHERYLAEEHFKAPVVVKNYPKDIKAFYMRLNEDG
KTVAAMDVLAPGIGEIIGGSQREERLDVLDERMLEMGLNKEDYWWYRDLRRYGTVP
HSGFGLGFERLIAYVTGVQNVRDVIPFPRTP
mrteycgqlrlshvgqqvtlcgwvnrrrdlgslifidmrdregivqvffdpdradalklaselrnefciqvtgtvrardek
ninrdmatgeievlassltiinradvLPLDSNHVNTEEARLKYRYLDLRRPEMAQRLKTRAKITSL
VRRFMDDHGFLDIETPMLTKATPEGARDYLVPSRVHKGKFYALPQSPQLFKQLLMMS
GFDRYYQIVKCFRDEDLRADRQPEFTQIDVETSFMTAPQVREVMEALVRHLWLEVKG
VDLGDFPVMTFAEAERRYGSDKPDLRNPMELTDVADLLRSVEFAVFAGPANDPKGRV
AALRVPGGASLTRKQIDEYDNFVKIYGAKGLAYIKVNERAKGLEGINSPVAKFLNAEIIE
AILDRTAAQDGDMIFFGADNKKIVADAMGALRLKVGKDLGLTDESKWAPLWVIDFP
MFEDDGEGGLTAMHHPFTSPKDMTAAELKAAPENAVANAYDMVINGYEVGGGSVRI
HNGDMQQTVFGILGINEEEQREKFGFLLDALKYGTPPHAGLAFGLDRLTMLLTGTDNI
RDVIAFPKttaa aclmteapsfanpaalaelsiqvvkkaenn
	
  
MLKIFNTLTRQKEEFKPIHAGEVGMYVCGITVYDLCHIGHGRTFVAFDVVAR
YLRFLGYKLKYVRNITDIDDKIIKRANENGESFVAMVDRMIAEMHKDFDALN
ILRPDMEPRATHHIAEIIELTEQLIAKGHAYVADNGDVMFDVPTDPTYGVLSR
QDLDQLQAGARVDVVDDKRNPMDFVLWKMSKEGEPSWPSPWGAGRPGWH
IECSAMNCKQLGNHFDIHGGGSDLMFPHHENEIAQSTCAHDGQYVNYWMHS
GMVMVDREKMSKSLGNFFTVRDVLKYYDAETVRYFLMSGHYRSQLNYseenl
kqaraaverlytalrgtdktvapaggeafearfieamdddfntpeaysvlfdmarevnrlkaedmaaanamashlrkl
savlglleqepeaflqsgaqaddsevaeiealiqqrldarkakdwaaadaardrlnemgivledgpqgttwrrk
	
  

Glutamine	
  

mseaearpTNFIRQIIDEDLASGKHTTVHTRFPPEPNGYLHIGHAKSICLNFGIAQD
YKGQCNLRFDDTNPVKEDIEYVESIKNDVEWLGFHWSGNVRYSSDYFDQLH
AYAIELINKGLAYVDELTPEQIREYRGTLTQPGKNSPYRDRSVEENLALFEKM
RTGGFEEGKACLRAKIDMASPFIVMRDPVLYRIKFAEHHQTGNKWCIYPMYD
FTHCISDALEGITHSLCTLEFQDNRRLYDWVLDNITIPVHPRQYEFSRlnleytvms
krklnqlvtdkhvegwddprmptisglrrrgytaaairefckrigvtkqdntiemaslesciredlnenapramavidp
vklviknyqgegemvtmpnhpnkpemgsrqvpfsgeiwidradfreeankqykrlvlgkevrlrnayvikaerve
kdaegnittifctydadtlskdpadgrkvkgvihwvsaahalpveirlydrlfsvpnpgaaddflsvinpeslvikqgfa
epslkdavagkafqferegyfcldsrhstaekpvfnrtvglrdtwakvge

Glutamate	
  

IKTRFAPSPTGYLHVGGARTALYSWLFARNHGGEFVLRIEDTDLERSTPEAIE
AIMDGMNWLSLEWDEGPYYQTKRFDRYNAVIDQMLEEGTAYKCYCSKERL
EALREEQMAKGEKPRYDGRCRHSHEHHADDEPCVVRFANPQEGSVVFDDQI
RGPIEFSNQELDDLIIRRTDGSPTYNFCVVVDDWDMEITHVIRGEDHINNTPRQ
INILKALNAPVPVYAHVSMINGDDGKKLSKRHGAVSVMQYRDDGYLPEALL
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NYLVRLGWSHGDQEIFTREEMIKYFTLNAVSKSASAFNTDKLLWLNHHYInal
ppeyvathlqwhieqenidtrngpqladlvkllgercktlkemaqscryfyedfaefdadaakkhlrpvarqplevvrd
klaaitdwtaenvhhaiatadelevgmgkvgmplrvavtgagqspaldvtvhaigktrsierinkaldfiaerenqq
	
  
Histidine	
  
(1KMM)	
  

KNIQAIRGMNDYLPGETAIWQRIEGTLKNVLGSYGYSEIRLPIVEQTPLFKRAI
GEVTDVVEKEMYTFEDRNGDSLTLRPEGTAGCVRAGIEHGLLYNQEQRLWY
IGPMFRHERPQKGRYRQFHQLGCEVFGLQGPDIDAELIMLTARWWRALGISE
HVTLELNSIGSLEARANYRDAlvafleqykdkldedckrrmytnplrvldsknpevqallndapalgd
yldeesrehfaglckllesagiaytvnqrlvrgldyynrtvfewvtnslgsqgtvcaggrydglveqlggratpavgfam
glerlvllvqavnpefkadpvvdislvasgadtqsaamalaerlrdelpgvklmtnhgggnfkkqfaradkwgarvav
vlgesevangtavvkdlrsgeqtavaqdsvaahlrtllg

Isoleucine	
  

msdykstlnlpetgFPMRGDLAKREPGMLARWTDDDLYGIIRAAKKGKKTFILHDG
PPYANGSIHIGHSVNKILKDIIIKSKGLSGYDSPYVPGWDCHGLPIELKVEQEY
GKPGEKFTAAEFRAKCREYAATQVDGQRKDFIRLGVLGDWSHPYLTMDFKT
EANIIRALGKIIGNGHLHKGAKPVHWCVDCRSALAEAEVEYYDKTSPSIVAFQ
AVDQDALKTKFGVSNVNGPISLVIWTTTPWTLPANRAISIAPDFDYALVQIDG
QAVILAKDLVESMQRIGVSDYTILGTVKGAELELLRFTHPFMDFDVPAILGDH
VTLDAGTGAVHTAPGHGPDDYVIGQKYGLETANPVGPDGTYLPGTYPTLDG
VNVFKANDIVVALLQEKGALLHVEKMQHSYPCCWRHKTPIIFRATPQWFVS
MDQKGLRAQSLKEIKGVQWIPDWGQARIESMVANRPDWCISRQRTWGVPM
SLFVHKDTEELHPRTLELMEEVAKRVEVDGIQAWWDLDAKEILGDEADQYV
KVPDTLDVWFDSGSTHSSVVDVRPEFAGHAADMYLEGSDQHRGWFMSSLMI
STAMKGKAPYRQVLTHGFTVDGQGRKMSKSIGNTVSPQDVMNKLGADILRL
WVASTDYTGEMAVSDEILKRAADSYRRIRNTARFLLANLNGFDPAKDMVKP
EEMVVLDRWAVGCAKAAQEDILKAYEAYDFHEVVQRLMRFCSVEMGSFYL
DIIKDRQYTAKADSVARRSCQTALYHIAEALVRWMAPILSFTADEVWGYLPG
EREkyvftgewyeglfgladseamndafwdellkvrgevnkvieqaradkkvggsleaavtlyaepelaakltalgd
elrfvlltsgatvadyndapadaqqsevlkglkvalskaegekcprcwhytqdvgkvaeyaeicgrcvsnvagdgekr
kfa

Leucine	
  

IESKVQLHWDEKRTFEVTEDESKEKYYCLSMLPYPSGRLHMGHVRNYTIGDV
IARYQRMLGKNVLQPIGWDAFGLPAEGAAVKNNTAPAPWTYDNIAYMKNQ
LKMLGFGYDWSRELATCTPEYYRWEQKCFTELYKKGLVYKKTSAVNWCPN
DQTVLANEQVIDGCCWRCDTKVERKEIPQWFIKITAYADELLNDLDKLDHWP
DTVKTMQRNWIGRSEGVEITFNVKDYDNTLTVYTTRPDTFMGCTYLAVAAG
HPLAQKAAENNPELAAFIDECRNTKVAEAEMATMEKKGVDTGFKAVHPLTG
EEIPVWAANFVLMEYGTGAVMAVPGHDQRDYEFASKYGLNIKPVILAADGS
EPDLSQQALTEKGVLFNSGEFNGLDHEAAFNAIADKLTEMGVGERKVNYRL
RDWGVSRQRYWGAPIPMVTLEDGTVMPTPDDQLPVILPEDVVMDGITSPIKA
DPEWAKTTVNGMPALRETDTFDTFMESSWYYARYTCPEYKEGMLDSKAAN
YWLPVDIYIGGIEHAIMHLLYFRFFHKLMRDAGMVNSDEPAKQLLCQGMVL
ADAFYYVGENGERNWVSPVDAIVERDEKGRIVKAKDAAGHELVYTGMSKM
SKSKNNGIDPQVMVERYGADTVRLFMMFASPADMTLEWQESGVEGANRFL
KRVWKLVYEHTAKGDVAALNVDALTEDQKALRRDVHKTIAKVTDDIGRRQ
TFNTAIAAIMELMNKLAKAPTDGEQDRALMQEALLAVVRMLNPFTPHICFTL
WQELKGEGDIDNAPWPvadekamvedstlvvvqvngkvrakitvpvdateeqvreragqehlvakyld
gvtvrkviyvpgkllnlvvg

Lysine	
  

mseqetrganeaidfndelrnrreklaalrqqgvafpndfrrdhtsdqlheefnakdnqeleslnievsvagrmmtrri
mgkasfvtlqdvggriqlyvardslpegvyndqfkkwdlgdiigargtlfktqtgelsihctelrlltkalrplpdkfhglq
dqevryrqryldliANDKSRQTFVVRSKILAAIRQFMVARGFMEVETPMMQVIPGGA
SARPFITHHNALDLDMYLRIAPELYLKRLVVGGFERVFEINRNFRNEGISVRH
NPEFTMMELYMAYADYHDLIELTESLFRTLAQEVLGTTKVTYGEHVFDFGKP
FEKLTMREAIKKYRPETDMADLDNFDAAKALAESIGITVEKSWGLGRIVTEIF
DEVAEAHLIQPTFITEYPAEVSPLARRNDVNPEITDRFEFFIGGREIGNGFSELN
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Methionine	
  	
  

DAEDQAERFQEQVNAKAAGDDEAMFYDEDYVTALEYGLPPTAGLGIGIDRM
IMLFTNSHTIRDVILFPAMRP
AKKILVTCASPYANGSIHLGHMLEHIQADVWVRYQRMRGHEVNFICADDAH
GTPIMLKAQQLGITPEQMIGEMSQEHQTDFAGFNISYDNYHSTHSEENRQLSE
LIYSRLKENGFIKNRTISQLYDPEKGMFLPDRFVKGTCPKCKSPDQYGDNCEV
CGATYSPTELIEPKSVVSGATPVMRDSEHFFFDLPSFSEMLQAWTRSGALQEQ
VANKMQEWFESGLQQWDISRDAPYFGFEIPNAPGKYFYVWLDAPIGLMGSF
KNLCDKRGDSVSFDEYWKKDSTAELYHFIGKGIVYFLSLFWPAMLEGSNFRK
PSNLFVHGYVTVNGAKMSKSRGTFIKASTWLNHFDADSLRYYYTAKLSSRID
DIDLNLEDFVQRVNADIVNKVVNLASRNAGFINKRFDGVLASELADPQLYKT
FTDAAEVIGEAWESREFGKAVREIMALADLANRYVDEQAPWVVAKQEGRD
ADLQAICSMGINLFRVLMTYLKPVLPKLTERAEAFLNTELTWDGIQQPLLGH
KVNPFKALYNRIDMRQVEALVEASKeevkaaaapvtgpladdpiqetitfddfakvdlrvalienae
fvegsdkllrltldlggekrnvfsgirsaypdpqaligrhtimvanlaprkmrfgisegmvmaagpggkdifllspdag
akpghqvk
	
  

Phenylalanine	
  

Serine	
  

Threonine	
  

Tryptophan	
  

VDVSLPGASLFSGGDHPITLMERELVEIFRALGYQAVEGPEVESEFFNFDALNI
PENGPARDMWDTVGKTGEGFRLEGPDGEEVEGRLLLRTHTSPMQVRYMVA
HTPPFRIVVPGRVFRAEQTDATAEAVFHQLEGLVVGEGVNEGDLYGAIYELA
QALFGPDSKVRFQPVTFPFVEPGAQFAVWWPEGGKWLELGGAGMVGPNVF
QAVDAYRERLGDPPAYRGVTGFAFGLGVERLAMLRYGIPDIRYFAGTRGKFL
EQFKGVL
MLDPNLLRNEPDAVAEKLARRGFKLDVDKLGALEERRKVLQVKTENLQAER
NSRSKSIGQAKARGEDIEPLRLEVNKLGEELDAAKAELDALQAEIRDIALTIPN
LPADEVPVGKDENDNVEVSRWGTPREFDFEVRDHVTLGEMYSGLDFAAAVK
LTGSRFVVMKGQIARMHRALSQFMLDLHTEQHGYSENYVPYLVNQDTLYGT
GQLPKFAGDLFHTRPLEEEADTSNYALIPTAEVPLTNLVRGEIIDEDDLPIKMT
AHTPCFRSEAGSYGRDTRGLIRMHQFDKVEMVQIVRPEDSMAALEEMTGHA
EKVLQLLGLPYRKIILCTGDMGFGACKTYDLEVWIPAQNTYREISSCSNVWDF
QARRMQARCRSKSDKKTRLVHTLNGSGLAVGRTLVAVMENYQQADGRIEV
PEVLR PYMNGLEYI
matattkccnvftvrrgqtkkalnaylqrleeaakRDHRKIGKQLDLYHMQEEAPGMVFWHND
GWTIFRELEVFVRSKLKEYQYQEVKGPFMMDRVLWEKTGHWDNYKDAMFT
TSSENREYCIKPMNCPGHVQIFNQGLKSYRDLPLRMAEFGSCHRNEPSGSLHG
LGRVRGFTQDDAHIFCTEEQIRDEVNGCIRLVYDMYSTFGFEKIVVKLSTRPE
KRIGSDEMWDRAEADLAVALEENNIPFEYQLGEGAFYGPKIEFTLYDCLDRA
AQCGTVQLDFSLPSRLSASYVGEDNERKVPVMIHRAILGSMEVFIGILTEEFAG
FFPTWLAPVQVVIMNITDSQSEYVNELTQKLSNAGIRVKADLRNEKIGFKIRE
HTLRRVPYMLVCGDKEVESGKVAVRTRRGKDLGSMDVNEVIEKLQQEIRSR
SLKQLEE
MTKPIVFSGAQPSGELTIGNYMGALRQWINMQDDYHCIYCIVDQHAITVRQD
AQKLRKATLDTLALYLACGIDPEKSTIFVQSHVPEHAQLGWALNCYTYFGEL
SRMTQFKDKSARYAENINAGLFDYPVLMAADILLYQTNLVPVGEDQKQHLE
LSRDIAQRFNALYGDIFKVPEPFIPKSGARVMSLLEPTKKMSKSDDNRNNVIG
LLEDPKSVVKKIKRAVTDSDEPPVVRYDVQNKAGVSNLLDILSAVTGQSIPEL
EKQfegkmyghlkgevadavsgmltelqeryhrfrndeaflqqvmkdgaekasahasrtlkavyeaigfvakp
	
  

Tyrosine	
  

MASSNLIKQLQERGLVAQVTDEEALVERLAQGPIALYCGFDPTADSLHLGHL
VPLLCLKRFQQAGHKPVALVGGATGLIGDPSFKAAERKLNTEETVQEWVDKI
RKQVAPFLDFDCGENSAIAANNYDWFGNMNVLTFLRDIGKHFSVNQMINKE
AVKQRLNREDQGISFTEFSYNLLQGYDFACLNKQYGVVLQIGGSDQWGNITS
GIDLTRRLHQNQVFGLTVPLITKADGTKFGKTEGGAVWLDPKKTSPYKFYQF
WINTADADVYRFLKFFTFMSIEEINALEEEDKNSGKAPRAQYVLAEQVTRLV
HGEEGLQAAKRITECLFSGSLSALSEADFEQLAQDGVPMVKMEKGADLMQA
LVDSELQPSRGQARKTIASNAITINGEKQSDPEYFFKEEDRLFGRFTLLRRGKK
NYCLICWK
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Valine	
  
(1GAX)	
  

mknatfylldndttvdglsaveqlvceiaaerwrsgkrvliacedekqayrldealwarpaesfvphnlagegprggap
veiawpqkrsssprdilislrtsfadfataftevvdfvpyedslkqlarerykslprgwfqpeygnleimektynpqdieq
plyehwekqgyfkpngdesqesfcimipppnvtgslhmghafqqtimdtmiryqrmqgkntlwqvgtdhagiat
qmvverkiaaeegktrhdygreafidkiwewkaesggtitrqmrrlgnsvdwererftmdeglsndvkevfvrlyke
dliyrgkrlvnwdpklrtaisdlevenreskgsmwhirypladgaktadgkdylvvattpetllgdtgvavnpedpryk
dligkyvilplvnrripivgdehadMEKTYNPQDIEQPLYEHWEKQGYFKPNGDESQESFC
IMIPPPNVTGSLHMGHAFQQTIMDTMIRYQRMQGKNTLWQVGTDHAGIATQ
MVVERKIAAEEGKTRHDYGREAFIDKIWEWKAESGGTITRQMRRLGNSVDW
ERERFTMDEGLSNAVKEVFVRLYKEDLIYRGKRLVNWDPKLRTAISDLEVEN
RESKGSMWHIRYPLADGAKTADGKDYLVVATTRPETLLGDTGVAVNPEDPR
YKDLIGKYVILPLVNRRIPIVGDEHADMEKGTGCVKITPAHDFNDYEVGKRH
ALPMINILTFDGDIRESAQVFDTKGNESDVYSSEIPAEFQKLERFAARKAVVA
AIDALGLLEEIKPHDLTVPYGDRGGVVIEPMLTDQWYVRADVLAKPAVEAVE
NGDIQFVPKQYENMYFSWMRDIQDWCISRQLWWGHRIPAWYDEAGNVYVG
RNEEEVRKENNLGADVALRQDEDVLDTWFSSALWTFSTLGWPENTDALRQF
HPTSVMVSGFDIIFFWIARMIMMTMHFIKDENGKPQVPFHTVYMTGLIRDDE
GQKMSKSKGNVIDPLDMVDGISLPELLEKRTGNMMQPQLADKIRKRTEKQFP
NGIEPHGTDALRFTLAALASTGRDINWDMKRLEGYRNFCNKLWNASRFVLM
NTEGQDCGFNGGEMTLSLADRWILAEFNQTIKAYREALDSFRFDIAAGILYEF
TWNQFCDWYLELTKPVMNGGTEAELRGTRHTLVTVLEGLLRLAHPIIPFITET
IWQrvkvlcgitadtimlqpfpqydasqvdeaaladtewlkqaivavrniraemniapgkplelllrgcsadaerrvn
enrgflqtlarlesitvlpaddkgpvsvtkiidgaellipmaglinkedelarlakevakiegeisrienklanegfvarape
aviakereklegyaeakaklieqqaviaal
	
  

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

72	
  

TABLE 3: Measured affinity constants used to create the binding matrix (in M).
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TABLE 4: Mutant vs. Native affinities for hisRS, metRS, pheRS.
NAAB	
  
Phenylalanine	
  
Histidine	
  
Methionine	
  
	
  

Native	
  Affinity	
  
62.9	
  µM	
  
294.0	
  µM	
  
305.1	
  µM	
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Engineered	
  Affinity	
  
3.4	
  µM	
  
68.2	
  µM	
  
60.7	
  µM	
  

CHAPTER 3:
A PROBABILISTIC FRAMEWORK FOR
PEPTIDE-SEQUENCING USING A SINGLE
MOLECULE ASSAY.

This chapter, along with chapter 2, will be compiled into a manuscript for submission to a
peer-review journal. Rob Mitra conceived the idea for parallel, single-molecule end
sequencing, while Jim Havranek originated the idea of using protein design to generate a
tool-kit. I carried out all experiments, simulations, and computational analysis in this
chapter as well as developing the Bayesian framework.
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ABSTRACT
As critical as design strategies are to the development of functional proteins for
practical applications, an iterative process between application and design can be an
important part of achieving the desired goals. In the previous chapter, I demonstrated
several techniques for improving protein-peptide affinities. Here, I demonstrate how
application-specific modeling of the assay, which takes advantage of information that
emerged in the engineering phase, can drastically improve results in the final application.
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INTRODUCTION
Protein engineering tools provide a wide range of benefits that can often be
effectively harnessed to generate new activities of affinities in biomolecules (1-9).
Despite these tools, there are situations in which it is impossible to generate the levels of
specificity required for a particular application. An effective combination of
computational modeling and application refinement may provide a way forward when
protein design reaches its limits.

A technique recently proposed by our collaborators attempts to implement a
parallelized variation of the Edman technique. This was briefly described in Chapter 2
(Figure 10), but will be explored in more depth here. Following a trypsin digest of a set
of proteins of interest, the resulting peptides are immobilized onto a glass slide coated in
a low-adsorption nanogel material with their N-termini projecting outwards from the
slide. The slide is then interrogated with a set of probes that bind at each N-terminal
amino acid according the affinity and specificity of each probe.

During each binding cycle (step 2-3 in Figure 10), a probe either does or does not
bind at a specific x-y coordinate on the chip. The spatial separation imposed by
immobilization of peptides on the slide allows each end-sequencing reaction to be carried
out in parallel. As envisioned, DAPES will return a set of Boolean vectors, one for each
cycle of binding and imaging at each spatial location on the array. Using probes for each

77	
  

amino acid except cysteine (thiol chemistry is utilized to couple the peptide to the
surface), we will have a 3-dimension matrix of dimensions n × m × p , where n is the
number of horizontal bins, m is the number of vertical bins, and p is the number of
€
probes, here 19. The matrix will consist of binary€
data as a result of any one complete
€
cycle of binding and cutting.

€

Utilizing the molecular tool-kit characterized in Chapter 2 to call individual
amino acids in a DAPES assay presents a number of problems. Chief among them is the
cross-specificity and redundancy of information made apparent by the cluster analysis in
Chapter 2. As previously mentioned, however, this is not an absolute barrier to utilizing
the tool-kit for its intended purpose. In fact, the cross-specificity may provide significant
advantages.

To see how cross-specificity could be beneficial consider an ideal set of NAABs
which would bind 10 of the 20 canonical amino acids with strong affinity and bind with
no appreciable affinity to the other 10. A single DAPES bind-image cycle will then
divide each amino acid into two groups. The second member of the ideal set of NAABs
would further divide each of the two groups into two more groups in a bind-image cycle,
and so on. If such NAABs were available, the cross-specificity would allow complete
identification of all amino acids with only five NAABs. While there is almost no
possibility that such NAABs could be engineered, it does demonstrate the utility of
binding subsets of amino acids rather than specifically binding only one.
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Here I demonstrate the suitability of the characterized set of NAABs for a single
molecule, protein-sequencing assay that utilizes N-terminal degradation and a novel
computational framework. While this assay is still in development, the computational
framework is applicable to any similar digital, single molecule assay on which such
binding events can be reliably imaged and recorded.

RESULTS
A Bayesian framework for de novo peptide identification.
A high-throughput, single molecule protein-sequencing assay, such as DAPES
(described above), will require the spatial segregation of individual peptides on a surface.
Sequential probing with NAABs will then return a vector of binary binding events
(Figure 18). For example, vαβ = {1,0,1} implies that at coordinates of x = α, y = β the first
NAAB binds, the second does not and the 3rd also binds. We define this general vector of
€
position specific€binding events as Vαβ . Given that we have appreciable cross-specificity

between NAABs (Chapter 2), we can utilize this to quantify and improve our

€ amino acids on the peptide chain.
identification of individual

The quantity of interest is the probability that a specific amino acid is present

{

}

1
,...,Vαβn (where n is the number of
given an observed binding sequence Vαβi ∈ Vαβ
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€

(

)

NAABs used) is, P aaVαβ where aa ∈ {ala,cys,...,tyr} . Using Bayes theorem (10), we
have:
€

€

(

)

P aaVαβ =

€

(

)

P Vαβ aa P ( aa)

( )

P Vαβ

(

)

We can then define the probability P Vαβ aa directly from the binding matrix in Chapter
2 as:

€

(

)

( )

( ( ))(1 − b )

P Vαβ aai = ∑ Vαβj bij + ∑ 1 − Vαβj

€

j

j

(

ij

)

where we define the binding matrix B ≡ bij , as having components equal to the
probability of binding each NAAB ( j ) for its target and off-target substrates at a

€
specified concentration. The concentration at which the NAABs are added to the slide
€
play a critical role in our ability
to visualize bound molecules on the surface (Figure 17)
and is used to convert the binding affinities into probabilities (see methods).

We then define the prior probability of observing any individual amino acid,

P ( aa) where {aa} = {ala,cys,...,tyr} , as being identical to the theoretical background of
the organism from which the sample came. For example in the human proteome, the least

€

€ amino acid in E. coli is tryptophan at 1.0% so P aa = trp = 0.01, and the most
common
(
)

common is alanine at 13%, so P ( aa = ala) = 0.13 (11).

€
€
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The probability of observing a specific combination of binding/not binding

( )

events, P Vαβ , is calculated by summing over all of the expected values for each
sequence according to Bayes theorem. Equation 1 thus allows us to compute the

€ probability of a specific N-terminal amino acid being present at a coordinate on the array
at the position (α , β) , given that a specific binary vector is observed.

€

The full binding matrix demonstrates that there is sufficient information to
determine identities for all 19 assayable amino acids
To determine the ability of the NAAB tool-kit to call amino acids in a DAPES
assay, we ran simulations using all possible binary sequences with 17 entries (equivalent
to the number of NAABs). The Bayesian model outputs a likelihood of identifying each
amino acid given the observance of a particular combination of binding events, which I
will refer to as a footprint. The distribution of likelihoods for all possible footprints for
each amino acid is shown in Figure 19, and demonstrates that 82% of the time, footprints
are unlikely to be called as an amino acid if we apply a high probability (>95%) threshold
for calling. This is not necessarily detrimental, since it is more likely that each spot on the
DAPES array will be called according to it’s highest probability amino acid. In this case,
it will be important to have a single call for each sequence. If we relax the above criteria
to requiring a greater than 50% probability, then 71% of the time a given footprint will be
uniquely callable.
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One way to determine how good the tool-kit is, in absence of the ability to
conduct an actual sequencing assay, is to consider the maximal ability to identify
individual amino acids. This is formulated as a 19 amino acid vector of probabilities,
which we call the maximum probability of identification or MPI vector. The MPI vector
for the full tool-kit is shown in Figure 20. This demonstrates that using the designed toolkit, there is at least one observable sequence for each amino acid that can be called with a
greater than 85% probability. In fact, only tryptophan is called with a probability below
94%. This is due to the fact that tryptophan occurs less frequently than any other amino
acid and thus has a very low prior probability rather than any inherent gap in the set of
NAABs.

Enumeration and correlation with the full matrix reveals optimal
combinations of NAABs for any number of binders
We next wanted to determine if there were subsets of NAABs that would suffice
for calling amino acids in the DAPES assay. The motivation being that minimizing the
number of bind-image-wash-cut cycles may be important to the practicality of DAPES.
To determine which subsets of NAABs were optimal, we conducted simulations with all
possible subsets. The MPI vectors of amino acid calling were then compared to that of
the full matrix by computing the correlation coefficient of each. There are some flaws to
this approach; namely, we may find that calling more amino acids with a lower
probability may be desirable in the final version of DAPES. Or we may find that calling
groups of amino acids is more effective to provide high-confidence mapping back to the
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genome. In these cases, the MPI correlation would be a poor choice of metric to measure
the optimal set. However, the goal here is to demonstrate the general usefulness of the
tool-kit in determining amino acid identity, since we do not yet know what the final
application will require. To meet this goal, the correlation metric between MPI vectors is
sufficient.

The resulting optimal matrix correlations for between five and 16 NAABs is
shown in Figure 21. We observe that the correlation rapidly increases from five to ten
NAABs then slows considerably. Looking at the effects on each individual amino acid
(Figure 22), we see that many are above an 80% probability of identification with as low
as only eight or nine NAABs. Tryptophan lags behind considerably, again because of it’s
extremely low prior probability. The identity of NAABs chosen in each optimized subset
is shown in Figure 23.

Relaxing the identification requirements allows 95% of amino acids to be
identified with only 6 NAABs
As previously mentioned, we may benefit from calling an amino acid at every
point in the array rather than discarding low probability spots. This approach may be
more representative of what would be performed in an actual DAPES assay. The
probability of each amino acid call can then be compiled at the completion of bind-wash
cycles, and positions on the array with very low total probability distributions can be
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discarded. This precise threshold will be determined once it is feasible to run control
experiments on the DAPES single molecule platform. For now, if we choose to remove
the probability threshold, then the majority of amino acids can be called with only six
NAABs (Figure 24). The sole outlier at this point is tryptophan due to its low prior
probability. Again, once it is possible to run the DAPES assay, we may find it prudent to
either omit identification of tryptophan, or increase the number of NAABs to 11.

A fitness function for the optimal set of NAABs
In it’s finished form, DAPES will require us to make trade-offs between our
ability to discriminate amino acid identities and the speed or reliability of the assay.
Several important factors will play a role in determining the combination of NAABs to be
used in the assay. The number of cycles needed to identify amino acids is expected to be
a driving factor in the number of NAABs that it will be possible to use. Higher affinity
NAABs will require lower concentrations during the assay (or less incubation time),
which will reduce the amount of non-specific surface adsorption and perhaps allow less
harsh reagents during washing. The cost of using a set of NAABs should be proportional
to the number used, while the benefit realized should be proportional to the MPI vector
and the number of amino acids uniquely identified. A simple fitness function for
evaluating the correct number of NAABs to use in DAPES would then be:

 

φ = α ( M • It f t ) − βN

€
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where the vector M is the MPI, the vector I is a Boolean vector determining whether or

not an amino acid is called with a probability above some threshold (t) , f is the number
€
€
of footprints that map to at least one amino acid with a probability greater than the

threshold, and N is the number of NAABs used. α and β€are €
parameters that will
depend on the relative importance of high identification probabilities vs. number of
€

€
cycles.

€

DISCUSSION
We have computationally demonstrated that our designed biomolecular tool-kit
can be used in a single molecule protein-sequencing assay to call amino acid identities
with a high probability. Furthermore, this analysis can be computed in real time, as
binding cycles occur, or a posteriori, once all relevant data has been gathered. While the
practical effectiveness of the tool-kit will be determined only once we’ve solved several
limitations of our imaging and surface chemistries, this framework provides a strong
starting point for amino acid calling in the DAPES assay.

Bayes theorem has been informatively applied to study a wide-range of biological
phenomenon (12-17), especially studies of DNA sequence characteristics. The extension
here to calling and identifying amino acids is novel, especially as it is applied to the
single molecule sequencing technology being developed by our collaborators. The
framework provides additional information gained from an experimental procedure
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(DAPES) to improve the resolving power of the biomolecular tool-kit. A point to note is
the probe concentration dependence of binding probabilities. This presents a large hurdle
for single molecule application, since the protein concentrations required to observe
binding (generally µM) are much higher than are feasible (high pM). Our collaborators
are currently working on a modification to DAPES which will allow imaging of transient
binding events, which should attenuate this issue.

The main concern about this framework, and the identification of optimal sets of
binders is that all characterization of the NAABs was performed using a non-optical
technique and distinctly different surface than the DAPES assay uses. We may find that
the DAPES surface significantly alters bind affinities or (more likely) that higher than
µM affinities are required for single molecule imaging. If this proves to be the case, the
framework will remain applicable but the set of NAABs may have to be significantly
altered. At the very least, the full specificity matrix will have to be re-determined on any
alternate surface. We expect that it will be proportional to the matrix determined on the
BLI surface since any change in affinity due to surface characteristics should be
relatively uniform.

Within the demonstrated framework, we have limited ourselves to identifying
only the canonical amino acids. While this provides an important proof-of-principle for
the tool-kit the library of amino acids found in a protein sample is much larger when
post-translational modifications are taken into account. However, this is a limitation of
the NAABs within the tool-kit rather than the computational framework presented here. It
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is possible that the existing tool-kit will exhibit distinct binding profiles (and hence
unique footprints) for other post-translation modifications. Though we have recently
developed NAABs for the phospho-amino acids, and will target other small molecule
post-translation modifications moving forward. Instances where the modification is a
macromolecule, such as ubiquitination or SUMOylation, are unlikely to fit cleanly into
the framework, and alternative identification techniques will have to be explored to target
these.

The final caveat is in the optimization of sets of NAABs for protein sequencing.
We do not yet know whether minimizing the number of NAABs used or maximizing the
identification probability will be more important in the final assay. The optimal subsets
should therefore be viewed as a demonstration of how the computational framework
coupled with the tool-kit allows us to optimize the assay, rather than a fully optimized
version.

MATERIALS AND METHODS
Implementation of the framework
The above framework was implemented in C++ and simulations were run using
experimentally derived binding data for each NAAB as determined by BLI in Chapter 2.
Each affinity was converted into a binding probability. This is likely to be a process that
is particular to the actual surface composition utilized for the single molecule assay.
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However, the general framework presented here should suffice, given adjustment of the
relevant parameters. The energy of each binding interaction is determined by a ratio of
the observed Kd to the concentration of the binder present in the assay (C), then converted
to an energy using the function:

P ( Binding) =

1

( (

))

1+ exp −α log(C ) − log(K d )

Here α is a scaling factor that can be adjusted depending on surface properties and assay

€

conditions.

€

The binding probabilities are then used to compute P(aa|S) and P(S) as described
above. Prior probabilities used in the simulations and optimization are taken from an
estimation of the amino acid composition of the human proteome (11).

Simulations
All simulations were run using a stand-alone program developed for this purpose.
First, all possible binary footprints that could result from DAPES data collection were
generated for between 5 and 17 NAABs. Next, sets of binding submatrices were
generated with 5 to 17 NAABs and all possible combinations were tabulated. The
Bayesian framework was then applied to each submatrix for each corresponding set of
footprints. The output (one file for each submatrix) from these simulations was a set of all
footprint probabilities for each amino acid. The maximum likelihood probability vector
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was then extracted and compared to that of the full (17 NAAB) matrix by computing the
correlation coefficient.
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FIGURE 17: Binding matrix concentration dependence. Binding matrix as a function
of concentration of probe used in a single-molecule assay. In each matrix, the y-axis is
the NAAB type and the x-axis is the amino acid that is being probed with that NAAB.
Probabilities of binding at 500 uM (top left), 50 uM (top right), 5 uM (bottom left), and
500 nM (bottom right).

92	
  

FIGURE 18: Data collection for DAPES. The image on the left is from a single
molecule data acquisition run using the TIRF set-up which DAPES utilizes. The green
spots correspond to a targeted molecule (in our case, the N-terminus of a peptide) and the
red spots correspond to the binding molecule (the NAABs). At each position where a
NAAB is bound, we see overlap (in yellow). Yellow spots are thus recorded as a binding
event, or a 1 in the Boolean footprint, while green spots are recorded as a 0. The red spots
then indicate non-specific adsorption of the peptides onto the surface.
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FIGURE 19: Sequence mapping data (number of sequences). The cumulative
probability of identifying any of the 19 amino acids in our set is plotted against the cutoff probability. For example, if we require a 95% probability to call an amino acid then
the cumulative probability of calling an amino acid from all possible footprints is 18%.
At greater than 50%, this increases to 71% of all possible footprints.
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FIGURE 20: Maximum probability of identification for 19 amino acids. The
maximum probability of calling an amino acid using the full-set of NAABs is shown
below. An informed prior, based on human proteome amino acid frequencies, was
utilized. Tryptophan is the only amino acid with a probability of identification at less than
95%, and most amino acids are greater than 99%.
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FIGURE 21: Increasing correlation of submatrices. The correlation of the MPI vector
with the full set of NAABs is shown in the plot below. There is a rapid increase in the
correlation from around 5 to 9 binders, and only incremental increases thereafter.
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FIGURE 22: Increase in identification for each amino acid as a function of number
of NAABs. The y-axis is the maximum probability of calling an amino acid for
increasing number of NAABs (darkest bar is 6 NAABs, lightest is 17). As noted
previously, tryptophan is the most problematic amino acid to identify using the Bayesian
framework because of its low prior probability (1.3%).
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FIGURE 23: Optimal subsets of NAABs. For a fixed number of NAABs (which
corresponds to fixed number of bind-wash-image cycles in DAPES) the optimal subset,
computed by MPI correlation with the full matrix, is shown below.
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FIGURE 24: Amino acid calling with relaxed minimum probability requirements.
Under a system where each sequence is called at whatever amino acid is most probable,
the ability to identify more amino acids is possible with fewer binders. At just 6 NAABs,
all but tryptophan is identified, while 11 NAABs are required for the full set of 19 amino
acids.
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CHAPTER 4:
AUTOMATED SELECTION OF STABILIZING
MUTATIONS IN DESIGNED AND NATIVE
PROTEINS.

This chapter contains a manuscript published in December of 2012 in the Proceedings of
the National Academy of Sciences. PNAS allows the authors to reproduce published
work for inclusion in a thesis or dissertation without copyright release required. All
experiments and computational analysis were carried out by me. Jim Havranek and I
conceived and designed the research.

Citation:
Borgo, Benjamin, and James J. Havranek. "Automated selection of stabilizing mutations
in designed and natural proteins." Proceedings of the National Academy of Sciences
109.5 (2012): 1494-1499.
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ABSTRACT
This chapter demonstrates a general computational approach to the problem of
stabilizing designed and native proteins. Stabilization is critical when designing proteins
for biotechnological applications since the conditions in which they are to be utilized are
often much more harsh than the intracellular environment.
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INTRODUCTION
Well-packed hydrophobic cores are a hallmark of protein structure (1, 2).
Consistent with the central role the hydrophobic effect plays in protein stability, defects
in core packing are associated with decreased stability(3)and loss of conformational
specificity(4, 5). Analytical tools for the assessment of core packing are useful for
identifying errors in experimentally determined structures and for rationalizing and
predicting the effects of mutations on protein stability. Not surprisingly, the assembly of
well-packed cores has been a central goal for computational protein design since its
inception(6).

Despite this central focus, models generated by computational protein design
algorithms often exhibit poor hydrophobic packing. This is due to both the simplified
structural representation and the scoring methods used by standard design protocols.
Structurally, the protein backbone is treated as rigid, and different side chain orientations
are sampled at each position. These side chains are limited to a discrete set of commonly
observed conformations known as rotamers. This combination implies a limited ability
to fill arbitrary volumes compactly. The coarseness of this representation is exacerbated
by the scoring functions, which generally include some form of the Lennard-Jones atomatom interaction term taken from molecular mechanics. There is a severe and wellknown mismatch between the distances over which this term can vary strongly and the
resolution afforded by a rotameric representation of side chains. Xiang and Honig
addressed this problem by increasing the number of allowable rotamers until the scoring
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function could be satisfactorily sampled(7). More commonly, the scoring function is
modified to accommodate the rotameric representation. This can be accomplished by
reducing the atomic radii to mitigate clashes or by modifying the potential at short
distances (8, 9). Many such approaches were evaluated by Keating and coworkers(10).

When computational design does yield a well-packed core, the redesigned protein
often exhibits enhanced stability. Complementary steric interactions and an increase in
the amount of buried hydrophobic surface area have been shown to stabilize the folded
state of native proteins(11). Furthermore, small globular proteins with computationally
optimized hydrophobic cores have exhibited increases in TM up to 20° C(8, 12).
Increased stability additionally confers upon proteins the potential benefits of resistance
to proteolysis(13) and longer half-life in-vivo (14), two desirable properties for protein
therapeutics. Furthermore, enhanced thermostability can preserve enzymatic activity at
elevated temperatures(15), aiding in the development of biocatalysts. Consequently,
computational design for stability is likely to play a major role in future protein
engineering efforts.

What current computational design methods lack is a way forward when design
models are not well-packed. The initial backbone template may be randomly perturbed
in the hope that some new side chain arrangement will emerge, and the number of
allowable rotamers may be increased, but the fundamental problems often remain. In the
following, we present an automated protocol, RosettaVIP (Void Identification and
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Packing), for improving the packing of a structural model. We use the RosettaHoles
analysis tool(16, 17) and a simple geometric scoring function to identify a small set of
mutations that may yield improved packing. We are able to devote more effort towards
evaluating this reduced set of possibilities, including consideration of computationally
expensive refinement steps incorporating backbone flexibility and off-rotamer side chain
freedom. We demonstrate the utility of our approach by identifying 'rescue' mutations for
two previously reported designed proteins and verifying experimentally that the selected
mutations yield more stable proteins. We demonstrate the broader relevance of our
approach beyond designed proteins by identifying and verifying a set of mutations that
significantly stabilize a wild-type protein.

RESULTS
Fully redesigned proteins exhibit poorly packed hydrophobic cores
We selected a set of proteins from the PDB that satisfy a number of constraints
(see Methods) and subjected each to complete sequence redesign. Following design and
relaxation, two structural assessments (the RosettaHoles packing score(17) and a simple
tally of the number of buried, unsatisfied hydrogen bonds) identify problems that may
lead to destabilized conformations. The difference in the number of buried, unsatisfied
hydrogen bonds is small, though a clear trend is observed (Figure 1A). Packing quality as
assessed by RosettaHoles is strikingly better for the native proteins than for models of
proteins fully redesigned with Rosetta using either a standard or softened atomic
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representation (Figure 1B). Thus, the most obvious deficiency of designed proteins is in
their packing.

RosettaVIP: A protocol for the identification and resolution of packing flaws
in design models
To refine protein design models, we used a simplified energy function (ERosettaVIP,
see methods) implemented in the RosettaVIP ‘assessment-refinement’ protocol (Figure 2).
The protocol locates regions in the model which are not well-packed and attempts to
identify mutations that improve packing. After parameterizing the simplified energy
function on an independent training set (see Methods), we evaluated the energy function
on a series of previously characterized mutant proteins, and the full protocol on several
poorly packed proteins.

RosettaVIP recovers native amino acids and rotamer conformations from
destabilized mutant crystal structures
We first assessed the ability of our energy function to rescue mutant proteins with
cavity-creating core mutations. A collection of 24 mutations of large buried hydrophobic
residues to alanine was assembled with the further requirement that crystal structures be
available for both the native and mutant proteins. We modeled the reversion of the native
amino acid in the context of the mutant crystal structure. Comparison to the mutant
crystal structure yielded ΔΔE (difference in the respective energy function upon
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mutation). We determined the rate of true positive prediction for reversion to the native
(known to be favorable) with both our protocol and the current RosettaDesign protocol(9)
(Figure 1C). The former has an 83% true positive rate, compared to only 46% for the
latter, indicating an almost 2-fold improvement. Because the native structures are
available, we compared χ1, χ2 side chain dihedrals of the natives to the reversion models
generated by our algorithm. 93% (VIP) and 94% (RosettaDesign) of the models showed
accurate rotamer recovery.

RosettaVIP accurately predicts stabilizing non-native mutations in protein
cores
We selected a set of core hydrophobic mutations from the ProTherm database that
confer at least a 3° C increase in TM, and for which structures of the wild-type protein
have been determined. Each has a mutation that replaces a small, buried hydrophobic
residue with a larger one. Using the wild-type structure as a template, we determined if
RosettaVIP correctly predicted the mutation to be favorable. The algorithm performs
exceptionally well (Figure 1D), with a true positive rate of 93%. In contrast,
RosettaDesign had a true positive rate of only 40%.

RosettaVIP does not select unfavorable small-to-large and
volume-conserving point mutations
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We next addressed the possibility that our protocol is simply choosing larger
amino acids to fill voids without regard for local steric complementarity. We identified a
set of mutations in the ProTherm database that replaced buried hydrophobic residues with
residues of equal or greater volume, but which resulted in a decrease of at least 2° C in
TM. Using the wild-type structure as a template, we asked if RosettaVIP incorrectly
predicted the mutation to be favorable. For these mutations, RosettaVIP exhibits a false
positive rate of 23%, compared to 5% for RosettaDesign. The increase in false positives
relative to RosettaDesign is expected, given the softness of the modified potential.
Statistical analysis using Cohen’s kappa (k)(18) indicates a two-fold improvement
(k=.623 for RosettaVIP and k=.323 for RosettaDesign) of correctly classified mutations.

The protocol predicts mutations that stabilize a redesigned λ repressor
Dantas et. al. tested the ability of RosettaDesign to redesign completely nine small
globular proteins (19). Most of these redesigns shared less than 50% sequence identity
with the starting scaffold. Remarkably, many were significantly stabilized in comparison
to their native counterparts. Among the less successful designs was the DNA-binding
domain (residues 3-89) of λ repressor. The designed λ repressor (λ0) exhibited a clear
loss of cooperative folding compared to the wild-type (20), and adopted a molten globule
state(19). Examination of a predicted model for λ0 revealed several buried cavities not
present in the native structure. The RosettaHoles packing metric indicates a low
probability (.54) of native-like core packing.
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We subjected λ0 to iterative redesign using RosettaVIP. The protocol converged
after five design cycles to yield a four-fold mutant with a predicted ΔΔEmut of 8.5 energy
units, a reduction in buried void volume of 242.9 Å3, and a significant increase in packing
quality (Table 1, Figure3A-B). We expressed and purified this mutant (λ4) and
characterized the stability experimentally. The circular dichroism signal as a function of
temperature has a steep folded baseline with a cooperative unfolding event between
65° C and 75° C (Figure 3C, inset). We fit a two-state unfolding curve to the data and
obtained a TM of 72.01° C (Figure 3D). We also observed increased stability to
guanidine-induced denaturation, with a ΔG0H2O of 7.71 kcal mol-1 (5.01 kcal mol-1 more
stable than λ0).

Reversion of two mutations individually recovers native-like unfolding in a
redesigned λ repressor
We were concerned that the steep folded baseline of λ4 was indicative of partial
non-cooperative unfolding below 60° C. Visual inspection of the model showed that two
mutations (F64W and L75W) had a small but potentially significant amount of solvent
exposed non-polar surface area. While the interactions of these residues were considered
favorable by our protocol, the exposure of hydrophobic surface area is only minimally
penalized. We therefore decided to eliminate each of these mutations and characterize the
pair of triple mutants independently. We expressed and purified the three-fold mutants
(λ643 and λ753) to assess their conformational stability.
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Each of the triple mutants exhibited folding behavior more closely resembling the
native λ repressor, though the slope of the transition region is less steep in both instances.
Notably, the thermal denaturation temperature of λ753 is 60.2° C, which is approximately
4° C above that of the native protein. Chemical denaturation showed a steeper transition
for both triple mutants as well as a shift towards higher [GuHCl] midpoint relative to λ0.
The ΔG0H2O for λ643 and λ753 were determined to be 4.46 and 4.77 kcal mol-1, an increase
in stability of 1.76 and 2.07 kcal mol-1 over λ0.

A predicted point mutation in a Protein L redesign increases stability
Protein L was redesigned to 46% sequence identity in (19). Though the TM for the
redesigned protein was near 100° C, the ΔG0H2O was below that of the wild-type.
RosettaHoles analysis indicated a packing score of 0.58 for the original design PL0,
suggesting room for improved packing. We applied RosettaVIP to PL0 and identified a
pair of mutations that improved the Rosetta score and increased the packing score to 0.71.
The protein L mutant PLdouble was expressed and characterized by circular dichroism.
PLdouble exhibited a folded-unfolded transition that was clearly not two-state (Figure 5B,
triangles). Based on our computational results, we reasoned that one of the predicted
mutations might be a false positive, and therefore expressed and characterized the pair of
point mutants. This speculation turned out to be accurate, as the mutant PLA6W had a TM
similar to that of PL0 but a higher ΔG0H2O of 4.6 kcal mol-1 (Table 1, Figure 4). The
second mutant (PLF10W) exhibited non-cooperative thermal denaturation and was not
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assayed further. Inspection of a model of the F10W mutation shows that the mutant side
chain makes solvent-exposed (rather than buried) hydrophobic contacts. Automated
identification of this pathology will be addressed in future work.

RosettaVIP predicts five mutations that significantly improve the stability of a
native enzyme
Finally, we wished to assess the ability of RosettaVIP to improve the packing of a
native protein. We selected as our test case methionine aminopeptidase from E. coli
(eMAP), a 287 amino-acid protein with α/β topology and a molecular weight of 30 kDa
which we are familiar with from unrelated work. eMAP has a moderate denaturation
temperature (51.4° C) indicating potential for improved thermal tolerance. Application of
our protocol selected five mutations that conferred a predicted ΔΔE of -5.8 energy units
(Table 1, Figure 5).

We expressed the designed and native proteins and assayed them for stability by
monitoring denaturation via circular dichroism. The native protein unfolds cooperatively
at 51.4° C (Figure 5E). The five-fold mutant (eMAP5-fold) exhibits an increase in TM of
17.6° C. Chemical denaturation of eMAP5-fold shows a transition midpoint shifted to
higher GuHCl concentrations than eMAPwt. Fitting a two-state model to the guanidine
induced denaturation curve of eMAP5-fold yields a ΔG0H2O of 4.6 kcal mol-1 versus
3.2 kcal mol-1 for eMAPwt. To assess the success of RosettaVIP on a residue-by-residue
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basis, we expressed and characterized each of the five predicted point mutants. Three of
the five mutations (C45L, V207I, and V24I) made a positive contribution to stability with
ΔΔG ranging from 0.29 to 0.89 kcal mol-1. The two remaining mutants, A152I and
F156L were approximately neutral (Table 1).

DISCUSSION
We have introduced RosettaVIP, a fully automated protocol for selecting point
mutations that improve the quality of core packing of structural models, and shown that
enhancement of these interactions leads to increased thermodynamic stability. The
effectiveness of RosettaVIP was demonstrated computationally on several sets of
previously characterized mutants, and validated experimentally by stabilizing two
completely redesigned but under-packed proteins (λ repressor and Protein L), as well as a
native enzyme (eMAP). RosettaVIP has demonstrated a high success rate for identifying
favorable mutations despite its relative simplicity. The false positive rate for selected
mutations, while modest, necessitates experimental verification of each prediction.

RosettaVIP is meant to eliminate packing defects by selecting point mutations
rather than implementing complete redesign of the hydrophobic core, which generally has
given the largest improvements in stability for small globular proteins (8, 12, 19).
However, the automated protocol presented here selects a minimal set of mutable amino
acids to optimize stability. In contrast to a complete core redesign, application of our
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protocol is expected to minimize structural perturbation of the design scaffold. This is
likely to prove beneficial in many applications where retention of binding or enzymatic
activity is as important as increasing stability.

We expect that RosettaVIP will be particularly useful to the enzyme design
community, as we were able to realize a dramatic increase in denaturation temperature
while minimizing loss of activity. The stabilization of methionine aminopeptidase led to
an approximate 3-fold decrease in activity compared to native at room temperature.
Native activity is sharply decreased at 50° C, while the 5-fold mutant remains active
(Figure S1). That there is still room for improvement in both the design and refinement
process is evident given that the homologous aminopeptidase from P. furiosus has a
melting temperature in excess of 100° C and is fully active up to 90° C.

Although we have focused on core packing, a number of other structural traits can
influence protein stability. Fully satisfied, buried hydrogen bond networks, secondary
structure capping motifs, optimized surface electrostatics, and backbone rigidity imparted
by supporting residues are all known to contribute to the stability of the folded state. In
particular, we observe that buried, unsatisfied hydrogen bonds are more common in
design models than in experimental structures (Figure 1). We are currently working on
extensions to our protocol that can identify and resolve a broader range of structural
defects.
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MATERIALS AND METHODS
Computational assessment of a library of completely redesigned proteins
A set of 500 crystal structures was selected from the PDB database. Each protein
in the set is monomeric, smaller than 30 kDa, free of disulphide bonds, with a structure
solved to 1.8 Å resolution or higher. HETATM and water entries were removed prior to
analysis, and hydrogens were built with the Rosetta program. Each structure was
subjected to relaxation under the Rosetta fullatom potential(21, 22). Packing quality was
analyzed using the RosettaHoles metric(16, 17). A count of all buried, unsatisfied
hydrogen bonds was obtained using a SASA probe of 1.4 Å. Hydrogen bonds were
defined with a strict geometric criteria(23). To generate a library of fully redesigned
models, all structures were then subjected to sequence optimization and rotamer
repacking on a fixed backbone using RosettaDesign with both a standard and dampened
Lennard-Jones potential(9). The resulting structures were analyzed for packing quality
and buried, unsatisfied hydrogen bonds. Distributions were generated for each metric and
a normal curve was fit (p < 0.001 in all cases) to each.

VIP scoring term
In the RosettaVIP representation, each heavy atom in the initial structure is
represented as a 'cloud' with 3-dimensional Gaussian density:

(

2

ρ(r,R) = exp −( r − R) /σ 2

€

)
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where r is the distance from the center of an atom, R is its coordinate vector, and σ is the
variance. The variance can be thought of as defining the 'softness' of the atoms, with a
larger σ indicating softer atoms. σ was allowed to vary from 0.9 to 1.1 times the van der
Waals radius in increments of 0.05. It was empirically determined that a scaling factor of
0.95 yielded the best agreement with the three test sets, which is in line with previous
work (8, 10). The overlap integral for any single atom (ai) within a structure S is then:

E VIP (ai ) = ∑

j:a j ∈S
j≠i

∞

∫ ρ (r,R)ρ
i

j

(r,R)dr .

−∞

The standard full-atom RosettaDesign scoring function consists of a linear superposition

€
of terms including a 6-12 Lennard-Jones potential, the Lazaridis-Karplus implicit
solvation model, an empirical hydrogen-bond term, rotamer probabilities, and amino acid
probabilities based on ϕ, ψ orientations (21). We implemented a simplified version of
this scoring function, substituting the VIP score term for the Lennard-Jones repulsion,
and retaining only the Lennard-Jones attractive term and a term to penalize the exposure
of additional surface area. The surface area term was included to prevent the insertion of
amino acid-rotamer conformations that were solvent exposed. The weighted energy
function used for fixed backbone sampling was:

E RosettaVIP = −w1 E LJ r + w 2 E SASA + w 3 E VIP
Linear weights for each energy term were chosen to optimize the recovery of native

€
amino acid sequence from a randomly mutated structure. The training set consisted of a
library of 41 small, globular protein domains.

Native, positive and negative test sets
114	
  

We assembled a test set (the native set) of structurally characterized, void-creating
point mutations. For each mutation in the set, high resolution (1.8 Å) crystal structures
are available for both the wild-type and mutant proteins. All mutations introduced an
alanine residue at a fully buried position that decreased protein stability, as reported in
the ProTherm database (8-17-2010 release). We identified a second test set (the positive
set) consisting of fully-buried point mutations that increase side chain volume and confer
at least a 3° C increase in thermal denaturation temperature. High-resolution crystal
structures are only available for the wild-type proteins in this set. Mutations removing or
introducing polar amino acids were excluded. A final test set (the negative set) was
assembled from structurally characterized, fully-buried, volume increasing mutations that
resulted in a decrease in TM of at least 2° C.

Identification of mutable residues
Buried cavities were identified using RosettaHoles(16, 17), which fills voids in
the protein with 'cavity balls', pruning away any which have a non-zero solvent accessible
surface area. The remaining balls represent the empty space within the molecule.
Residues were defined as mutable if there is at least one side-chain atom within 7 Å of a
cavity ball and if the residue is apolar and not on the surface of the protein. The set of
mutable residues was subjected to one-at-a-time design using the RosettaVIP score within
the RosettaDesign framework. RosettaHoles also provides a stochastic metric for packing
quality that is based on a support vector machine trained against high-resolution crystal
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structures. The metric returns the probability that a model has a native-like packing
arrangement, and has been extensively validated(16, 17).

Computational design
RosettaDesign consists of a Monte Carlo engine for the rapid optimization of
sequence space and an energy function for scoring the search through sequence space.
The Rosetta framework is thoroughly described in a pair of recent reviews(21, 22). For
our purposes, the Monte Carlo search for favorable mutations is carried out on a fixed
backbone using either RosettaVIP or Rosettadamp_rep, a 'dampened repulsive' Rosetta full
atom scoring function(9). After identifying mutable residues and selecting several
optimal amino acid-rotamer combinations at these positions, the two top scoring
mutations are retained and both the backbone and side-chains are allowed to relax.
Relaxation is an existing Rosetta protocol that combines gradient minimization with
Metropolis-Monte Carlo sampling of rotamers over all residues in the protein(21).
Following relaxation the design is rescored with the standard Rosetta fullatom score and
compared to the starting structure, which gives ΔΔE in Table 1. The resulting model with
the best Rosetta all-atom energy is then passed back to RosettaHoles and the process
iterated until there is no further improvement in the final scoring step. Final designs were
assessed and selected by Rosetta energies, RosettaHoles packing score (16) and volume
of buried voids. An application encompassing the selection workflow (figure 2 and
supplementary text) will be made available as part of the Rosetta software suite, which is
freely available to academic users.
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Cloning, expression and purification
A gene encoding λ repressor was purchased from Integrated DNA Technologies
(IDT) and cloned into the pET42(a) expression vector (Novagen) upstream of a 6x histag. Methionine aminopeptidase was amplified from E. coli genomic DNA, cloned into
pET42(a) upstream of the 6x his-tag, and verified by sequencing. Proteins were
expressed using an autoinduction protocol(24). Proteins were purified by immobilized
metal affinity chromatography and concentrated by ultrafiltration. Identity and purity
were verified by SDS-PAGE. Purified protein was dialyzed against 50 mM potassium
phosphate, 100 mM sodium chloride (pH 7) for 24 hours. Concentrations were
determined by absorbance at 280 nm(25). Site-directed mutagenesis was accomplished
using the QuikChange protocol (Agilent Technologies) and verified by sequencing.

Circular dichroism
Far-UV circular dichroism spectra were collected on an Applied Photosystems
Chirascan spectrophotometer at protein concentrations of 20-30 µM. Temperature
induced denaturation (10-95° C) was determined by stepped ramping in 5° increments
with a 30 second set time at 222 nm in a 2 mm path length cuvette. For GuHCl induced
denaturation, temperature was maintained at 25° C with a Peltier temperature control
device and denaturation was determined by monitoring change in ellipticity for 0-8 M
GuHCl in 0.5 M increments at 222 nm in a 10 mm path length cuvette.
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Data analysis
Thermal denaturation curves were fit to a two-state model by converting to
fraction folded (26):

Ff =

θ − θu
θ f − θu

and then by non-linear least squares to the equation:

€
⎛ ⎛
⎞
T ⎞
exp⎜ΔH⎜1−
⎟ RT ⎟
⎝ ⎝ TM ⎠
⎠
Ff =
⎛ ⎛
⎞
⎞
T
1+ exp⎜ΔH⎜1−
⎟ RT ⎟
⎝ ⎝ TM ⎠
⎠

(a rearrangement of the Gibbs-Helmholtz equation with Δcp = 0) to determine TM and the
€

van't Hoff enthalpy ΔH. Chemical denaturation curves were fit for all parameters by nonlinear least squares according to the formulas in ref. (27) to determine ΔG0H2O and m, and
converted to fraction folded according to ref. (26).
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FIGURE 25: Redesigned proteins exhibit decreased optimality of native-like
hydrogen bonding and packing interactions. A set of 500 fully redesigned scaffolds
exhibited an increase in buried, unsatisfied hydrogen bonds (A) and a decrease in packing
quality (B) both of which can confer decreased stability. ‘Experimental’ refers to the
unmodified crystal structures from the PDB. ‘Hard spheres’ refers to same set of
structures refined using the traditional Lennard-Jones potential (Rosetta ‘standard’ energy
weights), while ‘soft spheres’ refers to the structures refined with a modified LennardJones potential with reduced steric clashes (Rosetta ‘damp_rep’ energy weights). The
RosettaVIP protocol successfully predicts stabilizing point mutations in a variety of
different proteins. Graphic representations of the sensitivity and specificity of the
algorithm are shown for the native (C), positive (D), and negative (E) test sets.
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FIGURE 26: Overview of the RosettaVIP protocol. RosettaVIP starts with a structural
model and identifies voids within the protein interior. These voids are used to select
'mutatable' residues that are potentially positioned to fill these gaps upon mutation to a
judiciously chosen amino acid. Each mutable residue is computationally optimized on a
fixed backbone with all other amino acids held fixed, and favorable mutations are
subjected to a full relaxation in which the backbone is allowed to move. This restricts the
application of backbone flexibility (which is computationally demanding) to mutations
likely to be favorable. The highest scoring design is kept and used as the starting structure
for an additional round of selection, optimization, and relaxation. The protocol
terminates when no further voids are identified.
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FIGURE 27: λ repressor redesign. Structural models (A-B) of predicted mutations and
denaturation experiments (C-D) for the rescued λ repressor. The protein backbone is
represented in blue 'cartoon' representation (All figures made in pymol(28)). Voids are
identified by yellow 'cavity balls' and mutated residues are represented as orange spheres.
The upper panels show the modeled effects of mutations chosen by our protocol from two
angles. The drastic reduction in buried void volume from λ0 to λ4 is indicative of
improved packing of the hydrophobic core. The lower panel (C-D) shows the
experimental determination of the mutants’ stability. Recovery of cooperative folding is
evident in both the temperature (C) and chemical (D) denaturation. The inset in panel C
shows the sloped, folded baseline for λ4 in the raw ellipticity data.
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FIGURE 28: Protein L redesign. RosettaHoles analysis identifies two small voids in a
model for PL0 (A), one of which is filled by the A6W mutation (orange) in PLdesign (B).
The other void is reduced by a secondary interaction, where the A6W mutation causes the
rotation of F8 into the void region. In (C), the fraction folded as a function of GuHCl
concentration is plotted for PL0(open circles), PLdouble(triangles), and PLA6W(closed
circles).
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FIGURE 29: Stabilizing mutations for eMAP. Modeled mutations (A-D) and induced
unfolding curves (E-F) for methionine aminopeptidase as monitored by circular
dichroism. The global reduction in buried void volume (A) is apparent from the
RosettaHoles annotated model of the structure. Local reductions in void volume (B-D)
around each mutated region are also apparent. The chemical and thermal melts (E and F)
for the 5-fold mutant and each point mutation is shown in the lower panels. The bold,
black lines are the native and 5-fold mutants while the dashed colored lines are each
individual point mutant as noted in the legend.
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TABLE 5: Thermodynamic parameters from experiments and Rosetta modeling
were calculated as described in the text. Details on the full atom Rosetta Energy function
can be found in ref. (22), while details on the experimental parameters can be found in
ref. (26).
Original Designed
Protein
Volburied (Å3

Packing

E

)

Score

TM

ΔG0H2O

m

λ0

-217.1

298.3

0.54

nc

2.7

0.8

PL0

-101.17

149.7

0.58

100

3.7

1.4

eMAPwt

-614.01

891.37

0.61

51.4

3.2

1.8

Mutants

ΔΔE

λ4

-8.5

55.4

0.70

72.0

5.0

1.7

λ643

-4.7

94.7

0.64

58.5

2.2

1.0

λ753

-5.0

88.6

0.69

60.2

2.2

1.1

PLA6W

-3.1

42.5

0.66

100

0.9

1.4

eMAP5-fold

-5.8

828.4

0.68

69.0

1.4

1.2

eMAPV24I

-3.1

867.4

0.61

56.1

0.4

1.3

eMAPC45L

-2.4

860.1

0.62

52.9

0.5

2.6

ΔΔG
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eMAPV207I

-3.9

862.2

0.62

58.8

0.9

0.9

eMAPA152I

-1.4

879.2

0.61

51.2

0.3

0.9

eMAPF156L

-0.6

887.4

0.60

51.1

0.2

1.1
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CHAPTER 5:
MOTIF-BASED DESIGN OF ENZYME
SPECIFICITY
This chapter consists of a manuscript published in February of 2014 in the peer-reviewed
journal Protein Science. Protein Science allows the reproduction of published work by
authors for use in dissertations without formal approval required. Jim Havranek
developed the computational approach and implemented the design algorithms. I
completed all experiments and subsequent data analysis.

Citation:
Borgo, Benjamin, and James J. Havranek. "Motif‐directed redesign of enzyme
specificity." Protein Science (2014).
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ABSTRACT
This chapter utilizes a previously described computational method for designing
functional interactions. It is a generalizable approach to redesigning enzyme and substrate
binding specificity in proteins. The model system on which it was tested (methionine
aminopeptidase) was a candidate for the NAAB design in chapter 2 which we abandoned
in favor of the aaRS scaffolds.
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INTRODUCTION
Computational protein design has advanced rapidly over the past decade. Despite
many impressive successes 1-9, generating novel, functional proteins with activity levels
similar to natural proteins remains challenging. Limitations in scoring functions,
structural representation, and search strategies provide ample opportunity for
improvement. A common strategy for circumventing these limitations is to incorporate
structural building blocks from experimentally determined structures. For example,
computational protein design typically involves the combinatorial selection of
experimentally observed amino acid conformations (rotamers) that optimize some
scoring function when arranged on the backbone of a native protein4,10-13. Similarly,
structure prediction algorithms often rely upon libraries of backbone fragments culled
from the protein databank to reduce the conformational space that must be sampled when
assembling structural models of proteins 14-18. This strategy involves a trade-off: native
structural building blocks ensure that our models contain plausible interactions, but bias
us towards what has already been observed. This can be particularly limiting for protein
design, which usually seeks to realize a novel function or specificity.

Two strategies for leveraging native protein structures present themselves in the
context of the design of protein function. At the macromolecular level, we can identify
proteins that carry out related functions as starting templates and attempt to preserve
aspects of this function while redesigning other residues to accommodate desired
changes. At the atomic level, we can identify specific interactions involving residues in
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unrelated proteins that may prove useful in achieving the change in function or specificity
that we require to move from a starting template to a novel molecule. We can direct the
choice of mutations required to repurpose the native template by focusing on recreating
previously observed interactions from other structural contexts. Using previously
observed functional interactions is likely to increase the odds of success for a given
protein engineering goal.

The transplantation of atomistic interactions onto a design template is challenging
because the backbone conformation of the template is unlikely to present an optimal
geometry to reproduce the interactions found in the native context. Introducing modest
backbone flexibility is likely to accommodate a large number of functional interactions,
but it is not possible to know a priori how the backbone should be deformed. We
previously described a computational algorithm for addressing this problem in the
context of protein-DNA interactions 19. We identify a set of previously observed
functional interactions (called motifs) and attempt to transplant them onto our design
template. A motif can be successfully incorporated if modest movement of the design
template backbone accommodates placement of the motif’s functional amino acid. A
previous computational approach to enzyme redesign utilized flexible backbones 20,
however, this did not rely on library of putative functional interactions and required
explicit selection of mutatable positions.
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In this report, we extend the method introduced in ref. 19 for selecting motifs
from a set of native interactions to confer a change in the specificity of an enzyme.
Starting with a library of potentially functional motifs, we implement an algorithm that
utilizes iterative cycles of backbone relaxation and motif placement followed by the
redesign of additional supporting mutations. The extended method is general in the sense
that it can be used to design for any target for which a comprehensive motif-library can
be gathered from databases or constructed from computations. We describe this
approach in detail, and demonstrate its effectiveness by altering the specificity and
activity of methionine aminopeptidase. Our results show that in this system the transfer of
residue-level functional interactions can alter substrate specificity while preserving
existing catalytic activity.

RESULTS
Computational redesign of specificity with backbone flexibility
Methionine aminopeptidase from E. coli (eMAP) is an essential metalloaminopeptidase responsible for post-translational removal of N-terminal methionine from
proteins. As shown in Figure 2, the N-terminal methionine is directly contacted by two
loop regions surrounding the active site. A number of residues required for catalysis have
been identified by mutagenesis 21-23, while those involved in substrate recognition are less
well-studied but can be inferred from the crystal structures. Comparing the apo and holo
forms of the protein (purple and white, respectively, in Figure 1) reveals a relatively rigid
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binding pocket that shifts only slightly during substrate recognition. This ‘lock-and-key’
binding site is amenable to specificity redesign since no large structural rearrangements
appear to be required to accommodate the substrate. We therefore sought to switch the
specificity for N-terminal methionine to specificity for N-terminal leucine using motifbased design. This is a relatively stringent test for specificity redesign since leucine and
methionine both have similar hydrophobic properties and are comparable in size24.

Flexible backbone design can be directed by interaction motifs
A loop region of the protein recognizes the sidechain of the methionine substrate.
We anticipated that the loop region would need to rearrange to recognize a leucine
sidechain. Because optimal loop conformations for recognition cannot be determined in
the absence of side chain-side chain interactions, we employed motif-directed design. In
this approach, a library of previously observed amino acid-amino acid contacts is
collected from a set of experimentally determined structures.

Each motif in the library is used to place a free, interacting amino acid in the
appropriate location to realize the interaction with the desired leucine substrate. An
inverse rotamer library 19 is used to sample the side chain degrees of freedom of the
introduced amino acid. This yields a set of virtual amino acids poised to reproduce
previously observed interactions with leucine, each with an enumerated set of backbone
locations that could give rise to the interaction. A computational procedure is employed
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to search for interactions with the substrate that can easily be incorporated into the
preexisting backbone of eMAP with a limited amount of conformation rearrangement.

Using this approach, we identified residue-level interactions that could be
accommodated by the eMAP backbone with conformational flexibility. The first is an
interaction between two leucine residues (Figure 2A-B) taken from GTP cyclohydrolase
II (positions 47A and 18A, pdb code: 2BZ1 25). The second is between residues
Leu428A and Ile378A (Figure 2C-D) from estrogen receptor a (pdb code: 2IOK 26). To
maximize flexibility during the search for compatible backbone-motif matches, we
changed residues within the loop to alanine, with the exception of glycine and proline
amino acids, which were unchanged. Following the iterative incorporation of the two
interaction motifs, non-motif residues within the loop were redesigned using the
RosettaDesign 27 program (Figure 3). This process was repeated ten times, with backbone
relaxation performed between each sequence redesign calculation 28,29. The resulting
protein is denoted eLAP, and differs from eMAP at 19 positions (Figure 4).

Inactive eMAP exhibits binding specificity for N-terminal methionine
peptides
In the presence of a metal chelator, we found that eMAP binds N-terminal
methionine non-catalytically. We first conducted bio-layer interferometry (BLI)
experiments to measure the affinity of native eMAP for an N-terminal methionine peptide
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ligand. The results indicate that methionine recognition by eMAP in the absence of
catalytic activity is a fairly weak interaction, with a dissociation constant of 2.65 mM.
Next, we assayed the binding activity of eMAP against an N-terminal leucine peptide
ligand. The measured dissociation constant was 54.2 mM (Table I). Thus, eMAP
exhibits a >20-fold specificity preference for N-terminal methionine over leucine (Figure
5, Table I).

Inactive eLAP exhibits altered specificity profiles for N-terminal methionine
and leucine
We next tested whether our designed eLAP protein possessed altered specificity
for the N-terminal methionine and leucine peptides. Ideally, a specificity ‘swap’ would
result not only in a change of relative binding preferences relative to eMAP (such a
mutant may still prefer methionine, but by a smaller amount), but in an absolute
preference for leucine over methionine. We first measured the affinity of eLAP for the Nterminal leucine peptide and found detectable binding with a dissociation constant of
0.83 µM. This is slightly better than the affinity of eMAP for the methioinine peptide. We
then attempted to confirm the specificity swap by measuring the eLAP affinity for
methionine. The resulting dissociation constant (Kd = 19.08 µM) is more than an order of
magnitude higher than eLAP for leucine. Thus, eLAP exhibits a 20-fold preference for
leucine over methionine (Figure 5), verifying that the mutant’s affinity profile is opposite
that of eMAP.
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Active eLAP exhibits altered activity for N-terminal methionine and leucine
substrates
To determine whether the change in binding specificity translates into a change in
substrate specificity, we characterized the enzymatic activity of both eMAP and eLAP
using a fluorogenic assay. When the substrate [Met/Leu]-AMC is cleaved, the liberated
AMC group fluoresces, allowing direct measurement of substrate accumulation. While
optimal eMAP activity is known to require longer peptide substrates for maximal
activity, we selected these substrates for ease of measurement, and because we are
interested in relative, rather than absolute, rates. The Met-AMC substrate is roughly
equivalent to a two-amino acid substrate, which according to previous reports should be
cleaved with an activity around 5% of that of a pentapeptide 30. We measured the
activities of both enzymes against both substrates. Initial velocities for each substrate
(RFU min−1) were converted to concentrations of released AMC, and initial velocities
(µM min−1) were plotted as a function of substrate concentration. We determined the
kinetic constants for both enzymes against Met-AMC and Leu-AMC; the results are
summarized in Table 7. The measured kcat/Km (catalytic efficiency) for eMAP against
the Met-AMC and Leu-AMc substrates was 0.74 sec-1 M-1 and 0.02 sec-1 M-1,
respectively (Figure 6). Thus, the catalytic efficiency of eMAP against Leu-AMC
substrate is approximately 2.7% of that against Met-AMC, similar to the relative
efficiencies found in a previous study utilizing pentapeptides (~3%) 30, indicating that
despite the difference in absolute magnitudes, the AMC substrate provides an accurate
measurement of relative catalytic efficiency.

136	
  

We next assayed the activity of eLAP against both substrates. The engineered
enzyme has a kcat/Km of .0056 sec-1 M-1 against Leu-AMC, and a kcat/Km of .0024 sec-1
M-1 against Met-AMC. While the lower activity activity indicates that our mutated
enzyme is significantly less efficient than the native for both substrates, eLAP is more
than twice as efficient at cleaving the Leu-AMC substrate than the Met-AMC. The Km of
eLAP for the methionine substrate is actually lower than the Km for the leucine substrate.
However, kcat is nearly two orders of magnitude worse. We speculate this is due to the
significantly greater conformational heterogeneity of the methionine side-chain and the
adoption of a greater variety of bound states, which though they are tightly associated,
render catalysis impossible. The notion of a less-ordered loop is consistent with an
observed decrease in solubility of eLAP versus eMAP.

DISCUSSION
The ability to engineer specific activities into proteins using computational
techniques has advanced rapidly over the past several years and has enormous potential
for generating novel therapeutics, industrial enzymes, and biotechnology tools. Current
algorithms rely heavily on harnessing the native properties of existing proteins, either
explicitly through the use of rotamers or implicitly through knowledge-based energy
terms, to reconstruct enzymes or proteins with altered activity or specificity. In
algorithms that explicitly target pre-defined interactions, stable modules that possess the
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desired properties are either designed or identified from a database of empirical structures
and computationally matched to a region in the target protein. This type of “buildingblock” approach to synthetic biology has become popular in metabolic engineering 31-34
and several reports have demonstrated its applicability to protein design 7,8,35,36.

Perhaps the most striking examples of module transplantation have been
generated as a product of de novo enzyme engineering. The Rosetta software suite’s
enzyme design protocol, for example, has successfully transplanted artificial active sites
onto native backbone scaffolds 7,9,37. While this is an extraordinary feat of protein
engineering, and a stringent test of our understanding of protein structure and function, de
novo design is a much more difficult problem than need be solved to generate novel
enzymatic activities for many practical applications. By contrast, redesign of native
enzymes requires less effort and can draw upon a supply of over 4,000 chemical activities
38

that could be amenable to redesign.

We note that although computational design with motif-directed backbone
flexibility was successful in this case, the two motifs that were incorporated into the
flexible region of the protein both involved hydrophobic residues. It remains to be seen
whether this approach will prove successful for the design of hydrogen-bonded or
electrostatic interactions, which has proven more difficult than design involving only
hydrophobic contacts 39,40. Hydrogen bonded interactions require more stringent
geometric constraints, and the many-body, networked nature of these interactions may be
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a poor fit for standard design schemes, which typically employ scoring functions that are
truncated at two-body terms.

In eMAP, the catalytic, metal-chelating residues are readily distinguished from
the side-chain specificity-determining residues. Approaches such as motif-directed
design are likely to work well in proteins where this is the case, or when the desired
function is limited to binding or recognition. In this study, eLAP exhibited binding
kinetics for an N-terminal leucine that were similar to those of eMAP for an N-terminal
methionine. In general, however, specificity, catalysis, and binding energy are intimately
entangled in enzymes 41. Our results from the enzymatic assays indicate that in the case
of eMAP this is minimal but still apparent, as the kcat of the designed eLAP is
significantly less than that of the native enzyme for both substrates. This may limit the
applicability of the residue level, motif-based approach for the design of certain novel
catalysts.

Despite this limitation, our results also suggest that this approach may work well
in combination with directed evolution. Directed evolution is very effective at
optimizing a pre-existing activity, but is often incapable of generating large, coordinated
changes to establish novel function. Our results demonstrate the ability of motif-based
computational design to change specificity, and to cope with a large number of mutations
(19 for eLAP relative to eMAP). While it is likely that not all mutations are essential for
our desired goal, such a large number of simultaneous mutations cannot be encoded in a
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genetic library. In cases where a preexisting activity is lacking, motif-based design may
thus allow protein engineers to generate a starting point that would not be discoverable by
directed evolution alone. It is also possible that directed evolution would be able to
identify additional mutations to improve upon the activity of eLAP.

MATERIALS AND METHODS
Construction of motif library
We extracted motifs from a subset of the PDB 42 obtained from the PISCES server
43,44

. We required that all structures be solved using x-ray crystallography to a resolution

of 1.6 Å or better, with R-factors of 0.25 or better, and that no two domains shared more
than 20% sequence identity. This yielded 1682 structures. For each structure, all
residue-residue interactions that include a leucine were scored using the Rosetta full-atom
scoring function. We isolated hydrophobic interactions by considering individual scoring
terms. If the total Lennard-Jones potential score was greater than -1.0 Rosetta energy
units (REU) (lower values are more favorable), the interaction was discarded. Otherwise,
the geometry between the sidechains was determined as previously described 19. Briefly,
a coordinate system is defined for each of the amino acids by pre-defined terminal heavy
atoms (e.g., Cg, Cd1, and Cd2 for leucine). The translation vector and rotation matrix
relating the coordinate systems between residues is obtained, and may be used to recreate
one interacting partner given the other. To eliminate redundant interactions, the
geometric transformation is checked against previously calculated examples. Any

140	
  

interaction whose translation vector and rotation matrix differ from another by less than
1.0 Å and 0.4 radians, respectively, are deemed to be redundant and are discarded. Each
such interaction (called a motif) is defined by the identities of the amino acids involved,
the atoms used to define the coordinate systems, and the transformation relating the two
systems. We call the resulting set of non-redundant, previously observed interactions a
motif library.

Design template preparation
The starting point for redesign calculations was the experimentally determined
structure for eMAP in complex with the transition state analog norleucine phosponate
(pdb code: 2GTX 45). We modeled a leucine amino acid superimposed upon the
norleucine phosponate, and predicted the favored side chain conformation using the
Rosetta program 46. The conformation of the leucine amino acid was held fixed for all
subsequent calculations. Residues 56-70 were selected as a loop region. In order to give
the loop region flexibility in accommodating interactions with the leucine substrate,
residues 56-70, as well as neighboring residues 42,46,81,101,177, and 221 were replaced
with alanine, with the exception of glycine and proline residues, which were not changed.

Motif incorporation
The procedure for motif-directed backbone movement and incorporation of
interacting virtual amino acids is given in detail in ref. 19. Briefly, the leucine-specific
motif library was used to generate possible interactions between the protein and the
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leucine substrate in two steps. First, the geometric information for each motif was used
to place a virtual interacting amino acid in contact with the substrate. The motif defines
the relative orientation of the terminal heavy atoms in the interacting amino acid.
Second, we made copies of each virtual amino acid that differed only in their side chain
torsion angles, which were taken from a rotamer library. Copies that clashed with the
substrate or residues outside the loop region, or that had main chain atoms too far from
any protein residue (rmsd > 2.0 Å over the Cβ, Cα, C, and N atoms) were discarded.
Thus, each motif in the motif library gives rise to multiple virtual amino acids, each
satisfying the geometric requirements of the motif interaction, but with different locations
for their backbone atoms.

We next determined whether the protein backbone atoms could be made to
superimpose with those of each virtual interacting amino acid. We performed loop
relaxation under the Rosetta scoring function augmented with harmonic constraints
between the Cβ, Cα, C, and N atoms of the amino acid and the corresponding atoms of the
closest backbone position in the flexible loop. Backbone movement was considered
successful if the final rmsd over the constrained atoms was below 1.o Å. In this case, the
virtual motif amino acid was modeled onto the backbone. As aligning the backbone
atoms causes the terminal atoms to shift, we performed a second round of loop relaxation
in which constraints are applied to restore the motif-defining terminal atoms to their ideal
locations. We accepted as successful those cases with final rmsd values below 1.0 Å.
These motif-incorporating models served as the starting point for further attempts to
incorporate additional motifs.
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Redesign of loop residues
Following the final motif placement, surrounding residues in the design region are
mutated to support the altered backbone conformation using a combination of standard
protocols for fixed backbone design and energy minimization from RosettaDesign 27.
First, we redesigned any positions in the flexible loop or the neighboring residues that
had been replaced with alanine prior to motif incorporation, excluding incorporated motif
residues. Then, the ‘backrub’ loop relaxation protocol was applied to the loop (residues
56-70) 29. We performed ten iterations of this combined procedure.

Cloning and mutagenesis
The gene for methionine aminopeptidase was amplified from E. coli genomic
DNA, cloned into the pET42(a) expression vector (Novagen, MA, USA) upstream of a
6× his-tag, and verified by sequencing. Site directed mutagenesis was done by the Kunkel
method, with oligos ordered from IDT and mutants verified by sequencing. Proteins were
expressed using an autoinduction protocol 47. Proteins were purified by immobilized
metal affinity chromatography, eluted with an imidazole gradient, and concentrated by
ultrafiltration. Identity and purity were verified by SDS-PAGE. Purified protein was
dialyzed against 1x phosphate buffered saline (pH 7.4) for 24 h, and stored in 50%
glycerol. Concentrations were determined by absorbance at 280 nm.

Binding Assays
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Substrate peptides with a sequence of X-GMMSC were obtained (Cel-Tek, TN,
USA), where X is either methionine or leucine. Biolayer interferometry using the BLItz
platform (Forte Bio, CA, USA) requires the immobilization of the substrate onto a fiber
optic tip coated with amine-reactive chemical groups. Each substrate was attached by:
activating the tip with a 0.4 M 1-ethyl-3-3-dimethylaminopropyl)-carbodiimide (EDC)
and 0.1 M N-hydroxysuccinimide (NHS) solution for 10 minutes, attaching a N-betaMaleimidopropionic acid hydrazide (BMPH) hetero-bifunctional crosslinker in 0.1 M
sodium borate at pH 8.5 to introduce an exposed, reactive thiol, quenching unreacted
amine-reactive groups with 1M ethanolamine, attaching the substrate by reacting the Cterminal Cysteine with the BMPH thiol, and quenching unreacted thiols with a solution of
50 mM cysteine and 1 M NaCl in 0.1 M sodium acetate at pH 4.3. The substrate derived
tips where then washed with 100 µM BSA and stripped to remove any protein
contaminants with 8 M Guanidine Chloride twice before starting the binding assay. To
measure affinity constants, each tip was first blanked against a 1x PBS buffer containing
no protein. 4 uL of 1x PBS containing 3.7 µM (eMAP) or 4.9 µM (eLAP) were loaded
and the association of the protein to the substrate was measured for two minutes. The tip
was transferred back into a 1x PBS blank and dissociation kinetics were measured for
two minutes. The tip surface was then washed with 8 M guanidine chloride to strip off
any remaining protein before the tip was reused. Negative controls with both BSA and
the buffer blank showed no association/dissociation curves. Data was globally fit using
the built-in BLItz software to a 1:1 binding model to determine kon, koff and KD.

Aminopeptidase assays
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Fluorogenic amino-methylcoumarin substrate (x-AMC, where x is either
methionine or leucine) were ordered from BaChem. Cleavage of AMC from the
substrates was monitored on a 96-well plate fluorometer using a Synergy 2 Multi-Mode
Microplate Reader (Bio-Tek, VT, USA) at an excitation wavelength 360 nm and an
emission wavelength 485 nm for all substrates. Assays were conducted on 96-well round
bottom black polystyrene microplates (Corning Life Sciences, MA, USA) in a reaction
volume of 150 µl containing 3.7 µM eMAP or 4.9 µM eLAP, assay buffer (1x PBS, pH
7.4) and substrate at concentrations ranging from 1 to 80 mM. Reaction mixtures were
held at 4° C during combining, pre-incubated for 1 hour at 25°C and started by addition
of 10 µM Cobalt Chloride to the mixture. Fluorescence accumulation was monitored
every 1 minute over a period of 60 minutes and relative fluorescence units were
converted to rates of substrate cleavage by calibration with a free AMC standard curve
(Sigma Aldrich, MO, USA). Reaction rates at steady state were calculated from the slope
of the fluorescence time courses by linear regression of initial velocities, and kinetic
parameters were calculated assuming Michaelis-Menten kinetics, v = Vmax(S)/(S)+Km by
non-linear regression in the R statistical software package.
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FIGURE 30: Motif-based Design Workflow. The motif-based design workflow starts
by building a culled library of native interactions and enumerating inverse rotamer
conformations from a pre-defined set of PDB files. The designer then selects an
appropriate backbone scaffold on which to attempt candidate mutations, and an
integration region. The algorithm then attempts to integrate each motif into the
predefined site, rejecting any placement that exceeds a user-defined cutoff score. The
majority of motifs from the library are rejected at this step, which can be performed
iteratively to incorporate more than one motif. Once the number of motifs requested by
the user are inserted, mutations in the integration region are made to accommodate the
motif placement using fixed-backbone design, and then minimized. This final step is
iterative, and the final output is the lowest scoring design.
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FIGURE 31: Holo-eMAP (PDB ID 2MAT{Lowther et al., 1999, Biochemistry, 38,
7678-7688}, white) shows minimal conformational changes (0.114 RMSD) when bound
with methionine (PDB ID 1C21{Lowther et al., 1999, Biochemistry, 38, 14810-14819}).
The residues which contact the substrate are shown in a stick representation.
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FIGURE 32: The placed motifs are shown here in their native background (A-B)
and in their final position in eLAP (C-D). The native contact orientation is maintained
through-out the design process by constraining the three atoms which define the motif
coordinate system. Backbone atoms are allowed to move in discrete ‘inverse-rotameric’
conformations to graft the motif into its acceptor position.
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FIGURE 33: eLAP design. (A) Initial placement of the LL motif (cyan, sphere
representation) pulls the remodeled loop (cyan, cartoon) inwards towards the substrate
(orange). This step repositions the loop from its native conformation (green). (B) A
second motif, the LI motif (purple, right) is placed adjacent to the substrate, and the loop
is again remodeled (purple, cartoon) to accommodate the new motif. The LL motif is
constrained in this step. (C) Residues surrounding both motifs in the loop region (black)
are mutated to support the dual-motif placement, and relaxed in 10 iterations. Resulting
loop movement is minimal, and the native interactions are maintained during remodeling.
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FIGURE 34: Alignment of methionine aminopeptidase with the final design for a
leucine aminopeptidase. The flexible loop region encompasses residues 56-70 with the
two motif placements shown in bright red. Additional mutations made to accommodate a
greater range of loop conformations are shown in bold letters.

eMAP 1 SIKTPEDIEKMRVAGRLAAEVLEMIEPYVKPGVSTGELDRICNDYIVNEQ
eLAP 1 SIKTPEDIEKMRVAGRLAAEVLEMIEPYVKPGVSTGELERICWDYIVNEQ

54 HAVSACLGYHGYPKSVCISINEVVCHGIPDDAKLLKDGDIVNIDVTVIKD
54 HATDSLTGHNGIDGHGSISINEVVCHGVPDDAKLLKDGDIVNIDVTVRKD

104 GFHGDTSKMFIVGKPTIMGERLCRITQESLYLALRMVKPGINLREIGAAI
104 GFHGDTSKMFIVGKPTIMGERLCRITQESLYLALRMVKPGINLREIGAAI

154 QKFVEAEGFSVVREYCGHGIGRGFHEEPQVLHYDSRETNVVLKPGMTFTI
154 QKFVEAEGFSVVREYCGHGIGRGHHEEPQVLHYDSRETNVVLKPGMTFTI

204 EPMVNAGKKEIRTMKDGWTVKTKDRSLSAQYEHTIVVTDNGCEILTLRKD
204 EPMVNAGKKEIRTMKDGSTVKTKDRSLSAQYEHTIVVTDNGCEILTLRKD

254 DTIPAIISHD
254 DTIPAIISHD
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FIGURE 35: Changes in specificity in designed eLAP. On, off and dissociation rates
for eMAP and eLAP show similar specificities (~20-fold affinity preference) for their
target substrates (A), indicating that motif-based design successfully changes the
specificity of eMAP. A comparison of binding to each substrate (B), shows that the
primary increase in affinity is for the positive design state (ie eLAP for leucine) rather
than against methionine. A raw sensogram used to derive the specificity comparisons is
shown in (C).
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FIGURE 36: Enzyme kinetics data for (A) eMAP cleaving methionine (eMAP-met),
(B) eMAP-leu, (C) eLAP-met, and (D) eLAP-leu. Best-fit curves using the MichaelisMenten model are overlaid along with error bars for reaction velocities measured in
triplicate. Parameters are listed in Table 7.
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TABLE 6: Binding parameters.
Protein/Peptide

Kon

Koff

Kd (µM)

Emap/Met

1.85x103

4.89x10-3

2.65

Emap/Leu

2.71x102

1.47x10-2

54.2

Elap/Met

2.14x102

4.08x10-3

19.1

Elap/Leu

1.72x103

1.42x10-3

0.826
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TABLE 7: Kinetic parameters.
Protein/Substrate

Kcat

Km

Kcat/Km

Emap/Met-AMC

0.0033

0.0044

0.7397

Emap/Leu-AMC

0.0031

0.157

0.0201

Elap/Met-AMC

8.22 x 10-5

0.0336

0.0024

Elap/Leu-AMC

3.48 x 10-4

0.0619

0.00562
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CHAPTER 6:
RATIONAL DESIGN OF A NOVEL ENZYME
TO CATALYZE THE EDMAN DEGREDATION
USING SUBSTRATE ASSISTED CATALYSIS.
The chapter contains a manuscript that is currently in preparation for submission to a
peer-reviewed journal. Jim Havranek developed the conceptual background and carried
out initial modeling steps. I completed the computational design along with all
experiments and data analysis.
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ABSTRACT
The protein sequencing framework introduced in Chapter 2 requires sequential
degradation of peptides immobilized to a surface. The surface integrity, measured by low
background adsorption of NAABs, must survive multiple rounds of bind-wash-image
cycles. Because the Edman degradation requires a harsh acid-based catalysis step, which
may affect surface integrity, it is detrimental to our ability to image at a single molecule
level in multiple DAPES rounds. This chapter describes our efforts to engineer an
enzyme to catalyze the Edman degradation.
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INTRODUCTION
The remarkable efficiency and specificity of biological catalysts make enzyme
design a critical target for the protein design field. Aside from being ‘readily’ modifiable
as opposed to chemical catalysts, biocatalysts are generally more efficient, more specific
to their respective substrates, require milder reaction conditions, and are more
environmentally friendly. Hundreds of different enzymatic processes are routinely carried
out in pharmaceutical, chemical, agricultural, and food industries (1-7). Products that
utilize these processes range from simple research reagents (e.g. restriction enzymes) to
commodity chemicals (e.g. fabric cleaners) and the number of applications continue to
expand rapidly (8-11). Despite these many successful applications, the potential of
biocatalysis is only beginning to be fully realized.

The computational design of novel biocatalysts to elaborate this potential is seen
as one of the most promising fields of protein design and has exploded in recent years.
Most computational protein design efforts focus on de novo enzyme design, which
requires the matching of a designed, chemically functional active site into a protein
scaffold (12). This approach has been notably been applied to generate enzymes for the
Diers-Alderase (13, 14) and Kemp elimination reactions (15). Another approach, known
as enzyme redesign, focuses on modifying an existing enzyme that possesses either an
active site or substrate specificity helpful for the target application (16-18). This latter
approach relies on many of the proven algorithms used in computational design, and
leads to a higher probability of producing an active enzyme. It is also commonly used as
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a rational starting point for experimentally-based protein design techniques, particularly
directed evolution (19).

Several strategies have been used to redesign native enzymes for novel substrates.
Most often, these designs center around active site chemistry and arranging the novel
substrate into a conformation similar to the native substrate then selecting supporting
mutations which reinforce the new specificity. A highly active designed enzyme can be
difficult to express and purify especially if, as in proteases, the target substrate is present
within the expression cells. An alternative mechanism for catalysis which side-steps this
problem is called substrate assisted catalysis.

In substrate-assisted catalysis, the substrate provides one or more functional group
required for the reaction to take place (20). Substrate assisted catalysis was first described
for native enzymes inactivated by mutation. These mutations remove amino acid side
chains critical to catalysis and result in the loss of activity. Several groups have
demonstrated that modified substrates with chemical moieties similar to those that had
been removed could rescue enzymatic activity. For example, when the serine component
of a catalytic triad (21) is removed from a serine protease, then reintroduced in a peptide
substrate a highly specific site for proteolytic cleavage is introduced (22). Substrate
assisted catalysis was used by several groups (23, 24) to redesign more specific variants
of proteases.
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We selected a cysteine protease scaffold and reengineered its specificity to
catalyze the Edman degradation reaction. We removed the nucleophilic cysteine and
adopted a substrate-assisted catalysis strategy analogous to the approach used with serine
proteases. The resulting enzyme exhibits specificity for the presence of the Edman
reagent, phenylisothiocyanate (PITC), at the N-terminus and catalyzes the removal of the
N-terminal derivatized amino acid with catalytic efficiencies (kcat/Km) of up to 104 sec-1
M-1. Additionally, we observed activity for all tested amino acid side chains in the
penultimate position, suggesting that the enzyme can substitute for the standard acidbased catalysis in the cleavage step of the Edman degradation.

RESULTS
Computational redesign of a cysteine protease to catalyze the Edman
degradation reaction
We identified several selection criteria for a design scaffold. First, we selected
only cysteine proteases. These enzymes are more likely to have the correct chemical
complementarily to the nucleophile on the substrate. In particular, the isothiocyanate
group on PITC will substitute for the cysteine in the scaffold. Second, we required that
the P1 position have an amino acid side-chain whose Cα − Cβ vector is oriented away
from the protein core and unoccluded by surrounding residues. This is desirable since we
wanted to eliminate dependence of catalytic€activity on the side-chain identity as this
position. We also selected enzymes that had a co-crystallized inhibitor with a terminal
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aromatic moiety. This allowed us to concentrate on engineering residues that, while in the
binding pocket, were distant from the catalytic residues.

These criteria led us to select the cysteine protease, cruzain, from Trypanosoma
Cruzei (PDB 1AIM (25)). A particularly attractive feature of this scaffold is its known
affinity for phenylalanine-like inhibitors (26). We then generated an Edman degradation
transitions state (see methods) and docked it within the scaffold by aligning the
nucleophilic cysteine with the isothiocyanate moiety. After modeling in the Edman
degradation transition state, we first mutated the active nucelophile (cys25) to a glycine
in order to remove any protease activity. Previous studies have shown that mutation of
the active-site cysteine reduces activity to background levels (27). We then modeled the
transition state substrate for the Edman degredation reaction, and docked this substrate
into the binding pocket. Using the Rosetta full atom energy function (28) to eliminate any
largely unfavorable mutations, we manually selected three additional mutations, which
after constrained relaxation, improved the computational binding energy for the TSsubstrate by 13.8 Rosetta Energy Units (REUs).

These three mutations were inspired by commonly occurring, favorable
interactions between chemical moieties. A leucine to tyrosine mutation at position 157
introduces a highly favorable ‘ring-to-edge’ interaction between the tyrosine and the
aromatic group on the substrate (29-31). Additionally, it caps the binding pocket which
helps to maintain the position of the substrate thiol near the original position of the
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catalytic cysteine, as seen in the alignment of the design with the original catalytic triad
(Figure 36). The introduction of an electron-rich cysteine at position 133 also introduces
a canonical interaction with the lower edge of the aromatic ring (32, 33). The final
mutation, glycine to serine at position 65 satisfies a solvent-exposed hydrogen bond on
the substrate by acting as a hydrogen bond donor. The resulting design (Figure 35) packs
tightly around the modeled substrate and places the substrate thiol in the correct
orientation to complete the catalytic triad. We refer to this designed variant of cruzain as
Edmanase.

Edmanase exhibits specificity for the Edman reagent
We expressed and characterized the four-fold mutant using a fluorescence-based
assay (described in the methods) that follows the accumulation of fluorescence as the
engineered enzyme cleaves the PITC-amino acid from the ‘N-terminus’ of an PITC-xAMC substrate (where x is a specific side chain). Low levels of fluorescence
accumulation for the negative controls (with BSA) are presumably due to the natural,
uncatalyzed rate of cleavage of the AMC substrate under mild aqueous conditions.
Minimal fluorescence accumulation is observed with the negative controls. Though
cleavage of the PITC- substrate with Edmanase is comparable to that of the PITC+ with
BSA, there is an increase in fluorescence accumulation for the PITC-derived AMC
compared to the underivatized AMC substrate of 280-fold (Figure 40, Table 9).
Specificity for the Edman reagent can also be seen by comparing the rate change for the
BSA PITC- and PITC+, where we see only a 57-fold increase.
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Edmanase exhibits enzymatic activity for all P1 residue side-chains
We next investigated whether or not the penultimate amino acid side chain
identity had an effect on the rate of catalysis. Our modeled substrate orients the amino
acid side chain away from the body of the protein, shown in Figure 37. As expected
based on the predicted structure of our design, cleavage occurred regardless of which
amino-acid side-chain was present in the fluorescent substrate (Figure 38). The rate of
catalysis did vary significantly, from an efficiency of around 104 sec-1 M-1 for asparagine
and alanine, to near 101 sec-1 M-1 for proline (Table 8). The aspAMC and alaAMC were
best cleaved with catalytic efficiencies both on the order of 104. The Km for the bulky
phenylalanine side-chain is similar to that of aspartate but lower than that of alanine. This
indicates that the size of the side-chain plays a role in the catalytic efficiency, however, it
does have a minimal effect and Edmanase acts as an enzyme for all amino acids tested.

Steric blocking of the active site attenuates activity
We expressed several mutated variants of the Edmanase to determine if the
substrate-assisted catalytic mechanism functioned as designed. First, we replaced gly25
with a valine. The bulkier valine side-chain was expected to block access to the binding
pocket, thus removing the potential to sterically enforce the catalytically active substrate
conformation. Because of the substrate-assisted catalysis mechanism, we expected that
this mutation would lead to a near complete attenuation of Edmanase activity. The mutant
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was expressed and characterized using the same fluorescence based assay. Figure 40
demonstrates that only trace levels of activity remain, comparable to background, and
that the attenuation of catalysis resulting from this substitution is over 1000-fold.

Removal of the candidate general base attenuates activity
Our approach to design by substrate-assisted catalysis utilizes a nucleophile on
the substrate molecule, but should also require a basic residue to enhance proton transfer
from the substrate (21). This has been shown to be required in other proteases that utilize
a structurally similar catalytic triad (34-36). In Edmanase, this role is predicted to be
fulfilled by his159. We therefore mutated this histidine to alanine, expecting a significant
reduction in the catalytic activity. Results from the fluorescence activity assay are shown
in Figure 40. While the reduction in activity is not as drastic as the gly25val mutant
(approximately 11-fold reduction compared to 516-fold), the difference in activities is
attributable to a reduction in the catalytic constant rather than the Km, which is consistent
with our catalytic mechanism.

Catalysis is inhibited with the addition of a substrate analogue
The two inactivating mutations provide evidence that the mechanism of catalysis
for Edmanase is the substrate assisted mechanism that was designed computationally. To
provide further support, we attempted to identify a substrate-analog inhibitor for
Edmanase. Searching through commercially available compounds yielded three potential

167	
  

molecules. We characterized the inhibition of activity in increasing concentrations of
inhibitors. One of the three candidates, 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone
showed notable inhibition of Edmanase. Figure 39 (left panel) shows the accumulation of
cleaved substrate as a function of time, and (right panel) the inhibitory curve. The Ki is
high (1.14 mM), indicating that 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone is only
a weak inhibitor, however, the fact that it does inhibit the reaction implies that the
structure of this molecule displaces potential substrate and provides further support for
our substrate-assisted mechanism.

DISCUSSION
The number of outstanding successes realized by scientists using computational
techniques to design enzymes has grown rapidly over the past several years. We have
previously noted the practicality of enzyme redesign versus de novo enzyme design. Here
we utilize a distinct approach to enzyme redesign using substrate-assisted catalysis,
which offers a number of advantages. Potentially toxic biologically active enzymes (like
peptidases) engineered to harness such a mechanism should be easier to express and
purify than enzymes utilizing more traditional mechanisms (eg. nucelophile-base triads)	
  
(37). These enzymes should also have a far more stringent specificity due to the absolute
requirement for the presence of the derivatized substrate for catalysis to occur (23, 38).
Another practical advantage is that the amount and complexity of calculations and design
choices based on chemical quantum theory are greatly reduced compared to de novo
active-site design.
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While the engineering of the Edmanase enzyme is an important component of the
biomolecular tool-kit for protein sequencing using DAPES, the strategies employed to
engineer it are unlikely to be easily carried over to other applications. This may change as
the number of available crystal structures grows and the chance of finding a co-crystal
structure with a near-target substrate increases. Our approach is more likely to be utilized
in combination with structural biology, where a co-crystal structure is determined in a
targeted fashion once a candidate has been identified. Still, in this case the use of
alternative protein engineering techniques, particularly directed evolution, is more apt to
be generally applicable.

We qualitatively observed that the solubility of each PITC-derived substrate
generally played a significant role in the catalytic efficiency. The more soluble substrates
(alaAMC and aspAMC) have higher catalytic efficiencies while metAMC and pheAMC
are lower. ArgAMC is an outlier, however, the fact that it is a positively charged sidechain may indicate that this substrate is cleaved less efficiently because of secondary
interactions with Edmanase. An HPLC analysis of the reaction products did not exhibit a
different relative quantity of uncleaved substrate with metAMC and pheAMC, which
would indicate that the rates derived from this assay are accurate. ProAMC also exhibited
drastically reduced activity, however, proline is known to be troublesome even in the
chemical Edman cleavage, so this reduction is not surprising.
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The utility of substrate-assisted catalysis as a mechanism for designed enzymes is
especially important to engineering novel activities for protein therapeutics, where
extremely high specificities will be required for practical use. This is especially true for
protease enzymes, which may be designed to selectively target viral peptides and
proteins. While the introduction of foreign modification agents, like the Edman reagent,
may be impossible, substrate-assisted catalysis may provide a viable strategy for
engineering proteases for therapeutic applications.

MATERIALS AND METHODS
Scaffold Selection
Selection of the cysteine protease, cruzain (PDB 1AIM), as a design scaffold was
done by manually searching the PDB for an enzyme meeting several criteria including: 1.
Presence of a substrate with a terminal aromatic group, 2. Presence of a nucleophilic
cysteine attacking group, 3. An active site in which the amino-acid side chain would be
solvent exposed and not involved in substrate recognition, and 4. An active site in which
a peptide substrate could be accommodated. This search returned only this single scaffold
as a potential hit.

Chemical Modeling
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The transition-state, substrate analogue was modeled using quantum simulation in
the GAMESS package (39), and geometry optimized at the RHF/6-31G level. The
substrate model was then docked into the active site of the cruzain scaffold by overlaying
the aromatic portion of the model with the substrate present in the cruzain co-crystal
structure. The position and conformation of the modeled substrate was finalized by
energy minimization using the Rosetta full atom energy function and constraints to
prevent large rigid body movement of the substrate.

Computational Design
Mutations to accommodate the modified specificity were chosen manually after
computational saturation mutagenesis of active site residues. First, residues that made
contact with the substrate were chosen by visual inspection. These residues were
computationally mutated to reasonable replacements that were chosen based on wellknown, native-like interaction motifs. In particular, the ring-to-edge motif between
tyr157 and the substrate and the thiol-edge interaction between cys133 and the substrate
are known to be preferred packing arrangements (29, 32). The Rosetta energies for the
individual and combined mutations were tabulated. The top mutations were visually
inspected, and the 4-fold mutant was chosen because of the presence of two canonical
interactions with the aromatic region of the substrate and the well-satisfied hydrogen
bonding.
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Substrates and Inhibitors
Single amino acid, amino-methylcoumarin (AMC) containing compounds were
obtained from BAChem (Bubendorf, Switzerland). These included Arg-AMC, AsnAMC, Phe-AMC, Met-AMC, Ala-AMC, and Pro-AMC. Phenylisothiocyanate (PITC)
was purchased from Thermo-scientific and derivatized to the N-terminus of each
substrate by incubating for 20 minutes at 50°C in a 250 µL solution of
acetonitrile:pyridine:water (10:5:1) with 5 µL of PITC. The derivatized substrate was
then dried by rotary evaporation and resuspended in 250 µL of 1x PBS. Inhibitor
compound, 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone, was obtained from SigmaAldrich (St. Louis, MO).

Enzyme purification
A synthetic gene containing the engineered enzyme was purchased from
GenScript, cloned between the NdeI and XhoI sites in the pet42(a) (Novagen) expression
vector, then transformed into BL-21(DE3) chemically competent cells. Protein was overexpressed following Studier’s auto-induction protocol. Bacterial cells were harvested by
centrifugation of the cell culture at 5000 rpm and 4 degrees for 10 minutes. Cells were
then resuspended in 1x PBS pH 7.4 with 10% glycerol and 6M guanidine chloride. Cells
were then lysed by sonication on ice. The cell lysate was centrifuged at 18000 rpm, 4
degrees for 20 minutes. The supernatent was then filtered through a 0.2 um cellulose
acetate filter. The filtered lysate was loaded onto a 5 mL HisTrap (Ni-NTA) column and
washed with 5 column volumes of binding buffer (50 mM Tris-HCl, 150 mM NaCl, 6M
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guanidine chloride, 25 mM imidazole). Bound protein was then eluted in 50 mM TrisHCl, 150 mM NaCl, 6M guanidine chloride, 500 mM imidazole. Purified fractions were
then refolded by successive, overnight dialyses into 1x PBS containing 5M, 3M, 1M,
0.5M, and 0M guanidine chloride. Purified protein was then prepared for SDS-PAGE
analysis by mixing 2 parts sample with 1 part 4x loading dye. Samples were analyzed on
16% SDS-PAGE gels, and visualized by Coomassie staining. Protein concentration was
determined using the calculated molar extinction coefficient and measuring the A280 on
an ND-8000 spectrophotometer (Thermo Fisher Scientific).

Activity measurements
All kinetic measurements were performed in a 96-well corning plate on a BioTek
Synergy2 plate reader at 30 degrees. Reactions were started by adding 5-20 µL of
purified enzyme to 150 µL of .1-10 mM substrate solution. Side-chain identity had a
significant effect on substrate solubility. Final enzyme concentration was between 1 nM
and 100 nM. The difference between maximum substrate concentration and enzyme
concentration was equal in all experiments. Fluorescence of the cleaved product was
measured by exciting at 370 nm (30 second intervals for 1-10 hours) and monitoring
emissions at 460 nm. Fluorescence accumulation was monitored every 30 seconds and
relative fluorescence units were converted to rates of substrate cleavage by calibration
with a free AMC standard curve (Sigma Aldrich, MO, USA). Reaction rates at steady
state were calculated from the slope of the fluorescence time courses by linear regression
of initial velocities, and kinetic parameters were calculated assuming Michaelis-Menten

173	
  

kinetics, v = Vmax(S)/(S)+Km by non-linear regression in the R statistical software
package.

Inhibition by 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone
Assays were conducted as above, with 5uM substrate, 100 nM enzyme, and 50031.25 µM 1-(2-anilino-5-methyl-1,3-thiazol-4-yl)-ethanone. Reaction velocity was
determined as above, plotted against the inverse of inhibitor concentration, and fit by
non-linear least squares to determine the inhibition constant.
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FIGURE 37: (A) The conformation of cruzain (PDB 1AIM) with the modeled PITCala transition state analogue in a space-filling representation. The loose
complementarity of the transition state analogue to the binding pocket is the primary
reason this molecule was chosen as a design scaffold. (B) The designed Edmanase in the
same representation as (A). (C) Stick representation showing the location of the four
Edmanase mutations relative to the transition state analogue.
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FIGURE 38. Transition state model for the Edman degradation.	
  The modeled
substrate used to introduce Edmanase activity into the cruzain scaffold (A), and an
alignment of the original catalytic triad from cruzain (B, purple) with the substrateassisted catalysis triad (B, black) of Edmanase.
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FIGURE 39: Four mutations alter the activity of cruzain to catalyze the Edman
degredation.	
  (A) The introduced mutations (black) over-laid on the original cruzain
residues (cyan). (B) The same mutations in the context of the cruzain scaffold showing
the completed catalytic triad.	
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FIGURE 40: Michaelis-menten curves for the Edmanase enzyme	
  for alaAMC (A),
aspAMC (B), metAMC (C), pheAMC (D), argAMC (E), and proAMC (F). Each
demonstrates the ability of Edmanase to cleave a PITC-derived N-terminal amino acid
with varying degrees of efficiency.
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FIGURE 41: Inhibition of the Edmanase enzyme by a transition state analogue.	
  The
left panel shows the directly assayed flouresence accumulation time course of the
uninhibitied Edmanase (black) against varying concentrations of inhibitor (colored lines).
The right panel is the inhibition curve derived from the time course and fit to obtain the
Ki .
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FIGURE 42: Catalytic efficiency of Edmanase and mutants.	
  	
  A plot showing the
calculated catalytic efficiencies of the negative controls (BSA) and knock-out mutants
compared to that of Edmanase.
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TABLE 8: Kinetic parameters of Edmanase for AMC substrates.
Substrate	
  
Ala	
  
Asp	
  
Phe	
  
Met	
  
Pro	
  
Arg	
  
	
  

kcat	
  (s-1)	
  
.55	
  
3.6	
  
.47	
  
.54	
  
.0014	
  
.087	
  

Km	
  (µM)	
  
21.3	
  
124.5	
  
122.8	
  
271.8	
  
252.0	
  
167.8	
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kcat/Km	
  
2.6	
  x	
  104	
  
2.9	
  x	
  104	
  
3.8	
  x	
  103	
  
2.0	
  x	
  103	
  
5.7	
  x	
  101	
  
5.2	
  x	
  102	
  

TABLE 9: Kinetic parameters of Edmanase compared to attenuation mutants.
Variant	
  

kcat	
  

Km	
  (µM)	
  

kcat/Km	
  

Edmanase	
  
(Ala)	
  
G25V	
  
H159A	
  
BSA	
  (PITC-‐)	
  
BSA	
  (PITC+)	
  
Edmanase	
  
(PITC-‐)	
  
	
  

.55	
  

21.3	
  

2.6	
  x	
  104	
  

kcat(Edmanase)/	
  
kcat(Mutant)	
  
1	
  

.064	
  
.24	
  
.0018	
  
.067	
  
.082	
  

1,270	
  
96.1	
  
1,684	
  
1,090	
  
889	
  

50.4	
  
2.4	
  x	
  103	
  
1.07	
  
61.5	
  
92.2	
  

.116	
  
.436	
  
.0033	
  
.122	
  
.149	
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CHAPTER 7:
CONCLUSIONS AND FUTURE DIRECTIONS
	
  
	
  

Successful	
  design	
  of	
  novel	
  proteins	
  confronts	
  significant	
  challenges;	
  the	
  

combinatorial	
  complexity	
  of	
  the	
  search	
  process,	
  the	
  difficulties	
  in	
  modeling	
  subtle	
  
intra-‐molecular	
  interactions,	
  and	
  the	
  lack	
  of	
  a	
  full	
  understanding	
  of	
  protein	
  folding	
  
and	
  structural	
  determinants.	
  The	
  outlining	
  of	
  generalized	
  approaches	
  for	
  design	
  is	
  
therefore	
  essential	
  to	
  the	
  continued	
  success	
  of	
  the	
  field.	
  The	
  approaches	
  presented	
  
in	
  this	
  thesis	
  fall	
  into	
  two	
  general	
  categories:	
  codified	
  algorithms	
  and	
  strategies.	
  The	
  
former	
  is	
  the	
  cornerstone	
  of	
  computational	
  protein	
  design	
  and	
  was	
  outlined	
  in	
  
depth	
  in	
  the	
  introduction.	
  The	
  latter	
  provides	
  complementary	
  guidelines	
  of	
  
techniques	
  that	
  have	
  led	
  to	
  success	
  in	
  specific	
  cases	
  and	
  are	
  theoretically	
  applicable	
  
to	
  a	
  wide	
  variety	
  of	
  applications.	
  Both	
  are	
  essential	
  to	
  moving	
  the	
  field	
  forward.	
  	
  
	
  
	
  

Computational	
  protein	
  design	
  is	
  rapidly	
  moving	
  towards	
  a	
  more	
  applied	
  

focus	
  and	
  being	
  called	
  upon	
  to	
  deliver	
  user	
  friendly,	
  fast,	
  accurate	
  tools	
  for	
  
researchers	
  in	
  the	
  biomedical	
  sciences.	
  More	
  than	
  ever,	
  these	
  scientists	
  are	
  from	
  
outside	
  disciplines,	
  and	
  seek	
  to	
  harness	
  the	
  power	
  of	
  biomolecular	
  design	
  to	
  
enhance	
  their	
  research.	
  Because	
  of	
  this	
  growing	
  trend,	
  it	
  is	
  critical	
  that	
  design	
  
algorithms	
  improve	
  their	
  ability	
  to	
  generate	
  productive	
  protein	
  variants.	
  In	
  the	
  
fourth	
  and	
  fifth	
  chapters	
  of	
  this	
  thesis,	
  I	
  described	
  the	
  formulation	
  and	
  validation	
  of	
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two	
  techniques,	
  one	
  for	
  stabilizing	
  proteins	
  and	
  the	
  other	
  for	
  engineering	
  novel	
  
specificities	
  or	
  activities	
  into	
  an	
  enzyme.	
  The	
  former	
  approach	
  allows	
  us	
  to	
  improve	
  
the	
  design	
  process	
  by	
  providing	
  a	
  way	
  forward	
  when	
  conventional	
  approaches	
  fail	
  
to	
  design	
  a	
  well-‐packed	
  core.	
  More	
  generally,	
  it	
  is	
  an	
  example	
  of	
  iterative	
  design	
  
refinement	
  that	
  can	
  be	
  extended	
  to	
  a	
  variety	
  of	
  structural	
  anomalies	
  that	
  present	
  
themselves	
  due	
  to	
  the	
  necessary	
  simplification	
  of	
  physical	
  force-‐fields	
  for	
  
computational	
  design.	
  The	
  latter	
  approach	
  provides	
  a	
  computational	
  framework	
  to	
  
accomplish	
  what	
  we	
  refer	
  to	
  as	
  minimalist	
  design.	
  This	
  relies	
  on	
  harnessing	
  native	
  
interactions	
  with	
  the	
  hypothesis	
  that	
  those	
  interactions	
  which	
  occur	
  in	
  nature	
  are	
  
more	
  likely	
  to	
  be	
  realizable	
  in	
  design.	
  It	
  also	
  relies	
  on	
  the	
  more	
  over-‐arching	
  
principle	
  of	
  identifying	
  a	
  highly	
  favorable	
  scaffold	
  and	
  changing	
  as	
  few	
  amino	
  acids	
  
as	
  possible.	
  Chapter	
  2	
  of	
  this	
  thesis	
  exemplified	
  this	
  approach.	
  For	
  our	
  application	
  to	
  
the	
  development	
  of	
  a	
  protein	
  sequencing	
  tool-‐kit,	
  we	
  sought	
  absolute	
  specificity	
  for	
  
each	
  amino	
  acid	
  side-‐chain.	
  A	
  bottom-‐up	
  design	
  approach	
  would	
  have	
  required	
  us	
  to	
  
design	
  a	
  series	
  of	
  binding	
  pockets	
  for	
  a	
  set	
  of	
  extremely	
  similar	
  small	
  molecules.	
  In	
  
the	
  minimalist,	
  top-‐down	
  approach	
  to	
  protein	
  engineering,	
  scaffold	
  identification	
  
and	
  selection	
  are	
  critical	
  to	
  success.	
  The	
  minimalist	
  approach	
  led	
  us	
  to	
  select	
  the	
  
tRNA	
  synthetases	
  as	
  design	
  scaffolds	
  and	
  exploit	
  several	
  million	
  years	
  of	
  evolution	
  
to	
  obtain	
  the	
  desired	
  specificity.	
  We	
  focused	
  on	
  maintaining	
  that	
  specificity	
  while	
  
improving	
  the	
  protein	
  in	
  modest	
  ways,	
  such	
  as	
  removing	
  a	
  loop	
  to	
  increase	
  
substrate	
  accessibility,	
  which	
  we	
  were	
  more	
  confident	
  would	
  succeed.	
  In	
  the	
  
minimalist,	
  top-‐down	
  approach	
  to	
  protein	
  engineering,	
  scaffold	
  identification	
  and	
  
selection	
  are	
  critical	
  to	
  success.	
  We	
  demonstrate	
  that	
  this	
  is	
  the	
  case	
  with	
  both	
  the	
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Edmanase	
  enzyme	
  (Chapter	
  6)	
  and	
  the	
  biomolecular	
  tool-‐kit	
  of	
  NAABs	
  (Chapters	
  2	
  
and	
  3).	
  	
  
	
  
	
  

The	
  biomolecular	
  tool-‐kit	
  consisting	
  of	
  the	
  17	
  NAABs	
  and	
  the	
  Edmanase	
  

enzyme	
  in	
  combination	
  with	
  our	
  collaborators	
  work	
  on	
  the	
  single-‐molecule	
  TIRF	
  
assay	
  potentially	
  represent	
  a	
  huge	
  leap	
  forward	
  in	
  proteomics	
  technology.	
  The	
  
ability	
  to	
  sequence	
  proteins	
  on	
  a	
  highly	
  accurate,	
  high-‐throughput	
  platform	
  could	
  
revolutionize	
  protemics	
  in	
  the	
  same	
  way	
  that	
  next-‐gen	
  DNA	
  sequencing	
  has	
  
revolutionized	
  genomics.	
  As	
  our	
  collaborators	
  in	
  the	
  Mitra	
  Lab	
  work	
  diligently	
  
towards	
  making	
  DAPES	
  a	
  reality,	
  there	
  are	
  a	
  number	
  of	
  possibilities	
  for	
  refining	
  the	
  
set	
  of	
  NAABs.	
  Given	
  the	
  Bayesian	
  framework	
  introduced	
  in	
  Chapter	
  3,	
  we	
  have	
  a	
  
quantitative	
  way	
  to	
  determine	
  small	
  changes	
  in	
  specificity	
  that	
  could	
  reduce	
  the	
  
number	
  of	
  NAABs	
  required	
  for	
  amino	
  acid	
  calling	
  or	
  improve	
  the	
  probability	
  of	
  
identifying	
  amino	
  acids.	
  This	
  could	
  be	
  accomplished	
  by	
  inverting	
  the	
  optimization	
  
procedure	
  to	
  find	
  an	
  optimal	
  binding	
  matrix.	
  Constraints	
  upon	
  the	
  existing	
  matrix	
  
could	
  be	
  implemented	
  based	
  on	
  our	
  knowledge	
  of	
  the	
  current	
  tool-‐kit's	
  amenability	
  
to	
  design.	
  We	
  may	
  then	
  attempt	
  to	
  apply	
  the	
  minimalist	
  engineering	
  strategy	
  in	
  a	
  
guided	
  way	
  to	
  the	
  existing	
  set	
  of	
  NAABs.	
  
	
  
	
  

Additionally,	
  alternative	
  surface	
  platforms	
  can	
  be	
  explored.	
  Our	
  

characterization	
  of	
  the	
  tool-‐kit	
  relied	
  on	
  label-‐free	
  technology,	
  BLI,	
  which	
  is	
  similar	
  
to	
  SPR.	
  A	
  number	
  of	
  recent	
  studies	
  have	
  demonstrated	
  that	
  label-‐free	
  SPR	
  can	
  be	
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utilized	
  at	
  a	
  single	
  molecule	
  resolution,	
  though	
  there	
  are	
  still	
  significant	
  hurdles	
  to	
  
overcome.	
  If	
  such	
  a	
  technology	
  becomes	
  feasible,	
  it	
  could	
  help	
  to	
  side-‐step	
  the	
  
difficulties	
  of	
  combining	
  the	
  molecular	
  tool-‐kit	
  with	
  single	
  molecule	
  imaging.	
  
Ultimately,	
  this	
  thesis	
  work	
  in	
  applied	
  protein	
  design	
  has	
  been	
  successful	
  and	
  I	
  am	
  
confident	
  that	
  it	
  will	
  soon	
  be	
  applied	
  for	
  its	
  intended	
  purpose.	
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